CURRICULUM VITAE Luigi Cubeddu PERSONAL - College of ...

PERSONAL:
Name: Luigi Cubeddu
CURRICULUM VITAE
Luigi Cubeddu
Email. lcubeddu@nova.edu
lcubeddu@msmc.com
EDUCATION.
1957 - 1964 Central University of Venezuela M.D.
Caracas, Venezuela
1966 - 1968 Central University of Venezuela M.S.
School of Pharmacy
Department of Pharmacology and Toxicology
(Pharmacology - Suma Cum Laudem)
197l - 1974 University of Colorado Ph.D.
School of Medicine
Department of Pharmacology
(Pharmacology)
1974. University of Colorado. PostDoctoral
School of Medicine. Fellowship.
Department of Pharmacology.
2004. University of Guadalajara, Mexico. Clinical Specialist in Hypertension
and LatinAmerican Society of Hypertension
.
LICENSURE:
1965 Venezuelan Medical License, Physician #3714
1981 - 1984 North Carolina Memorial Hospital Physician Privilege License
1984 ECFMG Certification #366-076-8
1985 FLEX Certification (2-7-85)
1985 - Active North Carolina Medical License # 00-29195
2004 Clinical Specialist in Hypertension
2005 Florida Medical License ME-92341
POSTGRADUATE TRAINING IN MEDICINE
1964-1966 Two-years Internal Medicine Internship at the University Hospital, of the
Central University of Venezuela, Central University of Venezuela, Caracas,
Venezuela.

LUIGI X. CUBEDDU
1981-1984 Three-years supervised practice and training in Internal Medicine, Cardiology,
Nephrology and Intensive Care, at the Memorial Hospital of the University of
North Carolina at Chapel Hill.
1995-1996 Two-year training in Gastroenterology, focusing on upper GI pathologies,
endocoscopic evaluations and H Pylori-induced disease. Division of
Gastroenterology, University Hospital, Central University of Venezuela, Caracas,
Venezuela.
EMPLOYMENT HISTORY:
1998- Professor, School of Pharmacy, NOVA-Southeastern University, Florida, USA.
1994- 1996 Adjunct Faculty Member, Department of Pharmacodynamics, School of
Pharmacy, Southeastern University, Florida, USA.
1993 - Professor, Department of Pharmacology, School of Pharmacy, Central University
of Venezuela, Caracas, Venezuela.
1989 - 1993 Chairman, Department of Pharmacology, Central University of Venezuela, School
of Pharmacy, Caracas, Vernezuela.
1989 - Member of the Hypertension Unit: Hospital Perez Carreno of the City of Caracas.
1989 - 1997 Adjunct Faculty Member, Department of Medicine, University of North
Carolina at Chapel Hill
1989 - 1997 Adjunct Faculty Member, Department of Pharmacology, University of
North Carolina at Chapel Hill.
1983 - 1989 Member of the Faculty of the Neurobiology Curriculum
1982 - 1989 Member of the Graduate Faculty at the University of North Carolina at Chapel
Hill.
1982 - 1989 Member of the Hypertension Clinic at North Carolina Memorial Hospital.
1981 - 1989 Associate Professor of Pharmacology and Chief, Division of Clinical Pharmacology,
University of North Carolina at Chapel Hill.
1980 - 1981 Professor, Central University of Venezuela, School of Pharmacy, Dept. of Applied
Biological Sciences, Pharmacology Section.
1979 - 1981 Dean of Graduate School, School of Pharmacy, Central University of Venezuela.
1975 - 1978 Vice-President, Graduate Studies Committee, Central University of Venezuela.
1975 - 1976 Treasurer, Venezuelan Pharmacology Society.
1975 - 1980 Associate Professor, Central University of Venezuela, School of Pharmacy, Dept.
of Applied Biological Sciences, Pharmacology Section.
1974 - 1975 Temporary Faculty Member, Central University of Venezuela, School of Pharmacy,
Dept. of Pharmacology and Toxicology.
2

LUIGI X. CUBEDDU
1971 - 1974 Teaching activities in Pharmacology at the University of Colorado, School of
Medicine, Denver, Colorado. This covered teaching medical students in the
Pharmacology Ph.D. programs and in the Dept. of Obstetrics and Gynecology.
1968 - 1969 Acting Chairman of the Dept. of Pharmacology, Mid-West University, School of
Medicine, Barquisimeto, Venezuela.
1966 - 1968 Assistant Professor in Pharmacology, Mid-West University, School of Medicine,
Barquisimeto, Venezuela.
1964 - 1966 Two-years Physician Intern, University Hospital of Caracas, Venezuela.
1964 Teaching Assistant, Department of Pathology, School of Medicine, Central
University of Venezuela.
1962 - 1964 Student Intern, Perez de Leon Hospital, Caracas, Venezuela.
PROFESSIONAL SOCIETIES:
1999, 2002 American Medical Association
1989 - American Society for Hypertension
1982 - 1991 American Society for Pharmacology and Experimental Therapeutics
1986 - 1992 American Association for the Advancement of Science
1985 - 1991 American Society for Clinical Pharmacology and Therapeutics
1982 - 1991 Society for Neuroscience
1974 - Association of Professors of the Central University of Venezuela (APUC)
1964 - Venezuelan Medical Association
1968 - Venezuelan Pharmacology Society
1966 - Venezuelan Society for the Development of Science (ASOVAC)
PROFESSIONAL SERVICES:
2009- Congress Vicepresident: Ist Interamerican Congress on Diabetes. July 17 th -2010.
Maracaibo, Venezuela.
2005. Member of Committees for the development of criteria for the evaluation of
research and clinical faculty.
2005 Member of the Ad Hoc Graduate Program Committee. NSU
2004 - Congress Chair and Organizer: I International Congress of Therapeutics, XVII
Congress of Latin-American Association for Pharmacology., and I International
Congress of Natural health Products and Phytomedicines. http://therapeuticsalf.nova.edu
2004- Research Advisor, Dept of Internal Medicine, Mount Sinai Medical Center, Miami
Fl.
2003- Member Editorial Board Medical Science Monitor.
2000 - 2002 Corresponding Member of the Committee on Receptor Nomenclature and Drug
Classification (NC-IUPHAR).
2000 Vice-President Organizing Committee of Third Scientific Meeting of Latin-
American Society of Hypertension. Nov 1-4, 2000, Caracas, Venezuela.
2000 - 2004 Member of the Council for International Union for Pharmacology: IUPHAR,
Division of
Clinical Pharmacology.
.
2000 - Congress Chair and Organizer: I Congress International Therapeutics Society and
XVII Congress of Latin-American Association for pharmacology.
3

LUIGI X. CUBEDDU
2000 Elected President Latin-American Association for Pharmacology 2003-2006.
1998 - 1999 Faculty Member of the Latin American Steering Committee: COX-2 Science
Summit.
1996- 2000 Member of the National Committee for Biotechnology Development
Directly reporting to the President of Venezuela.
1995 - 1999 Member of the Editorial Board of the European J. of Pharmacology.
1993 - 1995 President Venezuelan Society for Pharmacology.
1989 - 1991 Consultant for Clinical Cardiovascular Research Division, Glaxo Inc.
1986 - 1992 Member of the Editorial Board of the Journal of Pharmacology and Experimental
Therapeutics.
1985 - 1989 Member of Medical Staff of North Carolina Memorial Hospital.
1984 - 1989 Member of the Clinical Research Unit Advisory Committee, University of North
Carolina.
1983 - 1989 Co-Director of Principles of Pharmacology Course, 2nd Year Medical Student
Pharmacology Course, University of North Carolina.
1983 - 1989 Member of the Faculty of the Neurobiology Curriculum, University of North
Carolina.
1982 - 1989 Consultant for the Pharmaceutical Industry (Pfizer, Knoll, Boehringer Mannheim,
Glaxo) in Clinical Pharmacology.
1982 - 1989 Member of the Graduate Faculty at the University of North Carolina.
1981 - 1989 Physician Member of the Hypertension Clinic at North Carolina Memorial Hospital.
1981 - 1989 Associate Professor of Pharmacology and Medicine, Univ. of North Carolina at
Chapel Hill.
1981 - 1989 Chief, Division of Clinical Pharmacology, School of Medicine, University of North
Carolina at Chapel Hill.
TEACHING RESPONSIBILITY (since 1981)
1998 Lecturer Cardiovascular Pharmacodynamics to PharmD programs.
NOVA-Southeastern Univ, Florida, USA.
1997 Lecturer in Diuretics and Cardiovascular Pharmacodynamics. Pharm D
Program. School of Pharmacy. NOVA -Southeastern University. Florida. USA.
1996 Lecturer of Cardiovascular Pharmacology, Pharm D program, School of
Pharmacy, NOVA-Southeastern University, Florida, USA.
1994- 1996 Lecturer of Cardiovascular Pharmacology, PharmD program, at School of
Pharmacy, Southeastern University, Florida, USA.
1989 - 1996 Lecturer in Therapeutics. Graduate program in Hospital Pharmacy. School of
1989 - 1995
Pharmacy. Central University of Venezuela.
Lecturer "Graduate Cardiovascular Pharmacology Course". School of Pharmacy.
Central University of Venezuela.
1989 - 1995 Course Director and Lecturer of "Pharmacology I and II". School of Pharmacy,
Central University of Venezuela.
1983 - 1989 Lecturer in Pharmacology, "Principles of Pharmacology and Toxicology", PHCO
202; UNC.
1985 - 1986 Coordination and Teaching of Hypertension Section in Mechanisms of Disease,
Medicine; UNC.
1984 - 1985 Training of Chief Medical Residents in research in Clinical Pharmacology, UNC
4

LUIGI X. CUBEDDU
1984 - 1986 Lecturer at the Resident's Reports Lectures to first and second year medical
residents on Drug Therapy, UNC
1982 - 1986 Coordinator and lecturer of the Clinical Pharmacology Conferences for
Housestaff and Faculty at North Carolina Memorial Hospital, UNC.
1982 - 1989 AHEC lecturer, Department of Medicine, UNC.
1982 - 1983 Hypertension Unit, Mechanism of Disease, 2nd Year, Medical Students, Small
Group Instructor, UNC
1982 - 1989 Main Lecturer, Course Codirector, Small Group Instructor, and Coordinator of
Small Groups in the Medical Pharmacology Course, UNC
1982 - 1989 Pharmacology 204, "Cardiovascular and Renal Pharmacology", UNC
1982 - 1983 Medicine 418, "Problems in Clinical Pharmacology", UNC
1982 - 1983 Pharmaco-Therapeutics, PhPr 177, "Therapeutics for Graduate Pharmacy
Students", UNC
1981 - 1983 Preceptor for Cardiology students in the Hypertension Clinic, North Carolina
Memorial Hospital, UNC.
Graduate Student MS or Ph.D. Thesis Advisor (since 1982)
1982 - 1986 Thesis Director for Mr. Michael James, Department of Pharmacology, UNC
1982 - 1986 Thesis Co-Director for Miss Diane Niedzwiecki, Department of Pharmacology,
UNC
1983 - 1987 Thesis Director for Mr. Eric Parker, Department of Pharmacology, UNC
1987 - 1988 Thesis Director for Mr. Tim Lovenberg, Department of Pharmacology, UNC
1991 - 1997 Thesis Director for Mrs. Ana Maria Castejon, Department of Pharmacology, UCV.
1991 - 1996 Thesis Director for Miss Beatriz Guevara, Department of Pharmacology, UCV.
1991- Thesis Director for Elizabeth Moreira, Department of Pharmacology, UCV.
Graduate Students/Fellow Trainees Current Position
(since 1982)
1982 Leslie Lerea, Ph.D., B.S. Postdoctoral Fellow, Dept. of Pharmacology,
Vanderbilt University, Nashville, TN
1983 Nancy Chamberlin, B.S. Postdoctoral Fellow, University of Chicago
1983 Mike James, Ph.D. Postdoc, Glaxo Co., Chapel Hill, N.C.
1983 Eric Parker, Ph.D. Postdoc, Univ. Texas Health Sci. Ctr., Dallas,
Texas
1984 Nancy Caplan, Pharm.D. Clinical Research Associate, Burroughs
Wellcome., Research Triangle Park, N.C.
1984-1985 Nery Fuenmayor, M.D. Nephrologist, M. Perez Carreno
1984-1985 Don Ferry, Ph.D. Senior Research Officer, Med. Res. Council,
Dunedin, New Zealand
1984-1985 Margaret Dean, M.D. Senior Lecturer, Univ. Adelaide, Australia
1984-1986 France Varin, Ph.D. Postdoc, Univ. Montreal, Canada
1985 Sherry Alcorn, M.D. Internist, Private Practice, N.C.
1985-1987 Pamela Diliberto, Ph.D. Fellow, Cell Biology & Anatomy, UNC-CH
1987-1988 Tim Lovenberg Graduate Student, Yale University
1989-1992 Vitdorys Gonzalez Study Coordinator and Student for MS degree
in Clinical and Hospital Pharmacy
1989-1990 Angela Gil Clinical Research Fellow
1989-1992 Yndhira Garcia Clinical Pharmacists.
1989-1990
1990-1991
Maria Andrade
Eliana C. Ochoa
Clinical Research Fellow
Clinical Research Fellow.
1990-1992 Angela Ceglia, MD. Clinical Research
1990-1992
1991-1992
Lorenzo Cedeño, MD.
Paola Pasquali,MD.
Clinical Research
Clinical Research
1991-1992 Ivonne Mandelblum Clinical Research Fellow
1991-1992 Simonetta Angelosante, MD. Clinical Research
1991-1992 Mitsuko Nashimura, MD. Clinical Research
1991-1993
1991- 1996
Lourdes Trujillo, MD.
Gabriela Faverola G.
Clinical Research
Clinical Research Fellow
5

LUIGI X. CUBEDDU
1992- 1996 Geraldine Morales N. Clinical Research Fellow
1993 -1996 Fatima Torrico Graduate Student
1993- 1995 Elizabeth Moreira Student for MS degree.
1994- 1996 Talina Tawid Clinical Research Fellow.
2004- Antonio Tristano Postdoctoral fellow
6

LUIGI X. CUBEDDU
AWARDS AND HONORS
2001 Best Scientific Paper at the VII Congress of the South-American Pharmaceutical
Federation.
2001 Honorific Mention at at the VII Congress of the South-American Pharmaceutical
Federation.
1999 Award: Dr. Francisco De Venanzi: prize to excellence and long-standing career
achievements in Medical Sciences.
1997 Award Antonio J. Muskus for Best Research Paper.
1995 Prize "Lorenzo Mendoza Fleury". Prize to scientific originality,
creativity and productivity: Best Scientist.
1993 Award Antonio J. Muskus for Best Research Paper.
1990 - Classified as High level Researcher by
The Venezuelan Research Council for the Development
of Science and Technology (CONICIT). Yearly evaluated.
1992 Award for Best Research: Venezuelan Society for Pharmacology.
1991 CONICIT Annual Award in Medical Sciences.
1981 CONICIT Annual Award in Medical Sciences
1980 CIFAVE Award for Medical Professionals
1979 Honorable Mention, Pedro Penzini Fleuri Award
1978 Honorable Mentions, l and 2, Area of Medical Sciences, CONICIT Annual Award to
the best scientific work.
1977 Honorable Mention, Sandoz Award
1976 Honorable Mention, Sandoz Award
1976 CIFAVE Award for Medical Professionals
1971 CIFAVE Award for Medical Professionals
7

LUIGI X. CUBEDDU
REVIEWED PUBLICATIONS:
1.Pluchino, S., Cubeddu, L.X. and Castaneda, M.L., and Rodriguez, Y. Interaction between norepinephrine and 5hydroxytryptamine
at the adrenergic receptor sites. Acta Cientifica Venezolana, 22:192-195, 1971.
2.Cubeddu, L.X., Mosimann, W. and Weiner, N. The effect of methylguanidine on norepinephrine metabolism in
isolated, perfused spleen and heart. J. Pharmacol. Exp. Ther. 188:93-106, 1974.
3.Cubeddu, L.X., Langer, S.Z. and Weiner, N. The relationship between alpha receptor block, inhibition of
norepinephrine uptake and the release and metabolism of 3H-norepinephrine. J. Pharmacol. Exp. Ther. 188:368-385,
1974.
4.Cubeddu, L.X., Barnes, E., Langer, S.Z. and Weiner, N. Release of norepinephrine and dopamine-beta-hydroxylase
by nerve stimulation l. Role of neuronal and extraneuronal uptake and of the alpha presynaptic receptors. J.
Pharmacol. Exp. Ther. 190:431-450, 1974.
5.Cubeddu, L.X., Barnes, E., Langer, S.Z. and Weiner, N. Release of norepinephrine and and dopamine-betahydroxylase
by nerve stimulation ll. Effect of papaverine. J. Pharmacol. Exp. Ther. 191:444-457, 1974.
6.Cubeddu, L.X. and Weiner, N. Release of norepinephrine and dopamine-beta-hydroxylase by nerve stimulation lll.
Effects of norepinephrine depletion on the alpha presynaptic regulation of release. J. Pharmacol. Exp. Ther. 192:1-14,
1975.
7.Cubeddu, L.X., Barnes, E. and Weiner, N. Release of norepinephrine and dopamine-beta-hydroxylase by nerve
stimulation IV. An evaluation of a role for cyclic adenosine monophosphate. J. Pharmacol. Exp. Ther. 193:105-127,
1975.
8.Cubeddu, L.X. and Weiner, N. Release of norepinephrine and dopamine-beta-hydroxylase by nerve stimulation V.
Enhanced release associated with a glandular effect of a benzoquinolizine derivative with reserpine-like properties. J.
Pharmacol. Exp. Ther. 193:757-774, 1975.
9.Clark, R.B., Su, Y.F., Ortmann, R., Cubeddu, L.X., Johnson, G.L. and Perkins, J. Factors influencing the effect of
hormones on the accumulation of cyclic AMP in cultured human astrocytoma cells. Metabolism, 24:343-358, 1975.
10.Goldstein, D.J. and Cubeddu, L.X. Dopamine-beta-hydroxylase in human cerebrospinal fluid. J. Neurochem.
26:193-195, 1976.
11.Cubeddu, L.X., Gimenez, M. and Goldstein, D.J. Inhibition of phenyl-ethanolamine N-methyl transferase by
human cerebrospinal fluid: a sodium chloride effect. Biochem. Pharmacol. 25:2537-2538, 1976.
12.Su, Y.F., Cubeddu, L.X. and Perkins, J. Regulation of adenosine 3':5'-monophosphate content of human
astrocytoma cells: Desensitization to catecholamines and prostaglandins. J. Cyclic Nucleot. 2:257-270, 1976.
13.Su, Y.F., Johnson, G.L., Cubeddu, L.X., Leichtling, B.H., Ortmann, R. and Perkins, J. Regulation of adenosine 3':5'monophosphate
content of human astrocytoma cells: Mechanism of agonist specific desensitization. J. Cyclic Nucleot.
2:271-285, 1976.
14.Cubeddu, L.X., Talmaciu, R., Klahr, L., Davila, J. and Goldstein, D.J. Dopamine-beta-hydroxylase in essential
arterial hypertension. Excerpta Medica. 9-12, 1976.
15.Cubeddu, L.X. and Vargas, M. Effects of sodium chloride on phenyl-ethanolamine N-methyl transferase activity.
Molecular Pharmacology. 13:172-180, 1977.
16.Cubeddu, L.X., Santiago, E., Talmaciu, R. and Pinardi, G. Adrenal origin of the increase in plasma DBH and
catecholamines, induced by hemorrhagic hypotension, in dogs. J. Pharmacol. Exp. Ther. 203:587-197, 1977.
8

LUIGI X. CUBEDDU
17.Pinardi, G. and Cubeddu, L.X. Societies and honors in scientific investigation. Acta Cientifica Venezolana. 28:113,
1977.
18.Cubeddu, L.X. Metabolism of catecholamines and neurological diseases. Acta Cientifica Venezolana. 29:313-326,
1978.
19.Pinardi, G., Talmaciu, R., Santiago, E. and Cubeddu, L.X. Contribution of adrenal medulla, spleen and lymph to the
plasma levels of DBH and CA, induced by hemorrhagic hypotension in dogs. J. Pharmacol. Exp. Ther. 209:176-184,
1979.
20.Cubeddu, L.X., Hoffmann, I.S. and Paris, V. Effects of papaverine on the release and metabolism of dopamine in
the rat striatum. J. Pharmacol. Exp. Ther. 209:73-78, 1979.
21.Cubeddu, L.X., Hoffmann, I.S. and Ferrari, G.B. Metabolism and efflux of 3H-dopamine in rat neostriatum:
Presynaptic origin of 3H-DOPAC. J. Pharmacol. Exp. Ther. 209:165-175, 1979.
22.Cubeddu, L.X., Barbella, Y.R., Marrero, A., Trifaro, J.M. and Israel, A. Circulating pool and adrenal soluble
content of dopamine-beta-hydroxylase (DBH) in rats, guinea-pigs, dogs and humans: Their role in determining acute
stress-induced changes in plasma enzyme levels. J. Pharmacol. Exp. Ther. 211:271-279, 1980.
23.Hoffmann, I.S. and Cubeddu, L.X. Presynaptic effects of 2-aminotetralins on striatal dopaminergic neurons. J.
Pharmacol. Exp. Ther. 215:486-423, 1980.
24.Cubeddu, L.X., Davila, J., Zschaeck, D., Barbella, Y.R., Ordaz, P. and Dominquez, J. Cerebrospinal fluid and
plasma dopamine-beta-hydroxylase activity in human hypertension. Hypertension 3:448-455, 1981.
25.Wilson, S., Cubeddu, L.X., Chang, P. and Viveros, O.H. Met-enkephalin, Leu-enkephalin and other opiate-likepeptides
in human pheochromocytoma tumors. Neuropeptides 1:273-281, 1981.
26.Hoffmann, I.S. and Cubeddu, L.X. Presynaptic effects of tetrahydropapaveroline on striatal dopaminergic neurons.
J. Pharmacol. Exp. Ther. 220:16-22, 1982.
27. Hoffmann, I.S. and Cubeddu, L.X. Rate and duration of stimulation determines presynaptic effects of haloperidol
on dopaminergic neurons. J. Neurochemistry. 39:585-588, 1982.
28.Israel, A.S., Barbella, Y.R. and Cubeddu, L.X. Effects of chemical sympathectomy on the increases in plasma
catecholamines and dopamine-beta-hydroxylase induced by forced immobilization and insulin-induced hypoglycemia:
origin and fate of plasma DBH. J. Pharmacol. Exp. Ther. 221:577-583, 1982.
29.Cubeddu, L.X., Zarate, N.A., Rosales, C.B. and Zschaeck, D.W. Prazosin and propranolol in the preoperative
management of pheochromocytoma. Clin. Pharmacol. Ther. 32:156-160, 1982.
30.Cubeddu, L.X. and Hoffmann, I.S. Operational characteristics of the inhibitory feedback mechanism for regulation
of dopamine release, via presynaptic receptors. J. Pharmacol. Exp. Ther. 223:497-501, 1982.
31.Cubeddu, L.X., Wilson, S.P. and Viveros, D.H. Opioid-peptides and catecholamines in human pheochromocytoma.
Life Science. 33(9):871-877, 1983.
32.Rogers, J.F. and Cubeddu, L.X. Naloxone does not antagonize the antihypertensive effect of clonidine in patients
with essential hypertension. Clin. Pharmacol. Ther. 34:68-73, 1983.
33.Cubeddu, L.X. and Hoffmann, I.S. Frequency-dependent release of acetylcholine and dopamine from the rabbit
striatum. Its modulation by dopaminergic receptors. J.Neurochem. 41:94-101, 1983.
9

LUIGI X. CUBEDDU
34.Cubeddu, L.X., Hoffmann, I.S. and James, M.K. Frequency-dependent effects of neuronal uptake inhibitors on the
autoreceptor-mediated modulation of dopamine and acetylcholine release from the rabbit striatum. J. Pharmacol. Exp.
Ther. 226:88-94, 1983.
35.Cubeddu, L.X., Hoffmann, I.S., James, M.K. and Niedzwiecki, D.M. Changes in the sensitivity to apomorphine of
dopamine and acetylcholine release modulatory receptors after chronic treatment with bromocriptine or haloperidol. J.
Pharmacol. Exp. Ther. 226:680-685, 1983.
36.Hoffmann, I.S. and Cubeddu, L.X. Differential effects of bromocriptine on dopamine and acetylcholine release
modulatory receptors. J. Neurochem. 42: 278-282, 1984
37.Niedzwiecki, D.M., Mailman, R.B. and Cubeddu, L.X. Greater potency of mesoridazine and sulforidazine than
thioridazine on striatal dopamine autoreceptors. J. Pharmacol. Exp. Ther. 228:636-639, 1984
38.James, M.K. and Cubeddu, L.X. Frequency-dependent muscarinic receptor modulation of acetylcholine and
dopamine release from rabbit striatum. J. Pharmacol. Exp. Ther. 229:98-104, 1984
39.Cubeddu, L.X., Cloutier, G., Gross, K., Grippo, R., Tanner, L., Lerea, L., Shakarjian, M., Knowlton, G., Rogers,
J.F., Harden, T.K. and Arendshorst, W. Bupropion does not antagonize the cardiovascular actions of clonidine in
normal volunteers and in spontaneously hypertensive rats. Clin. Pharmacol. Ther. 35:576-584, 1984
40.Halperin, A., Gross, K.M., Rogers, J.F. and Cubeddu, L.X. Verapamil and propranolol in essential hypertension.
Clinical Pharm. Ther. 36:750-758, 1984
41.Cubeddu, L.X., Hoffmann, I.S., Davila, J., Barbella, Y.R. and Ordaz, P. Clonidine reduces elevated cerebrospinal
fluid catecholamine levels in patients with essential hypertension. Life Sciences. 35:1365-1371, 1984.
42. Martinez-Torres C, Cubeddu L.X., Dillmann E., Brengelmann GL., Leets I., Layrisse M, Johnson DG and Finch C.
Effect of exposure to low temperature on normal and iron-deficient subjects. Amer J Physiol 246: 380-383, 1984.
43. Parker, E.M. and Cubeddu, L.X. Evidence for autoreceptor modulation of endogenous dopamine release from
rabbit caudate nucleus In Vitro. J. Pharmacol. Exp. Ther. 232:492-500, 1985.
44.Cubeddu, L.X., Carr, M.E. and Fuenmayor, N.J. Beta blockade by oral propranolol and labetalol. Clin. Pharmacol.
Ther. 37:277-283, 1985.
45. Halperin, A. and Cubeddu, L.X. Role of calcium channel blockers in the treatment of hypertension. Am. Heart J.
111:363-382, 1986.
46. Cubeddu, L.X., Aranda, J., Singh, B., Klein, M., Brachfeld, J., Freis, E., Roman, J. and Eades, T. A Comparison of
Verapamil and Propanolol for the Initial Treatment of Hypertension: Racial Differences in Response. J. Am. Med.
Assoc. 256:2214-2221, 1986
47. Ferry, D.G., Caplan, N.B. and Cubeddu, L.X. Interaction between antidepressants and alpha adrenergic receptor
antagonists on the binding to alpha 1 acid glycoprotein. American Pharmaceutical Association. 75:146-149, 1986.
48. Parker, E.M. and Cubeddu, L.X. Effects of d-amphetamine and dopamine synthesis inhibitors on dopamine and
acetylcholine neurotransmission in the striatum. I. Release in the absence of vesicular transmitter stores. J. Pharmacol.
Exp. Ther. 237:179-192, 1986.
49. Parker, E.M. and Cubeddu, L.X. Effects of d-amphetamine and dopamine synthesis inhibitors on dopamine and
acetylcholine neurotransmission in the striatum. II. Release in the presence of vesicular transmitter stores. J.
Pharmacol. Exp. Ther. 237:193-203, 1986.
10

LUIGI X. CUBEDDU
50. Fuenmayor, N. and Cubeddu, L.X. Cardiovascular and endocrine effects of naloxone compared in normotensive
and hypertensive patients. Eur. J. Pharmacol. 126:189-197, 1986.
51. Hoffmann, I.S., Talmaciu, R.K. and Cubeddu, L.X. Interactions between endogenous dopamine and dopamine
agonists at release modulatory receptors and multiple actions of neuronal uptake inhibitors on transmitter release. J.
Pharmacol. Exp. Ther. 238:437-446, 1986.
52.Talmaciu, R.K., Hoffmann, I.S., and Cubeddu, L.X. DA autoreceptors modulate DA release from the prefrontal
cortex. J. Neurochem. 47:865-870, 1986.
53.Cubeddu, L.X. Racial difference in response to antihypertensive drugs: A focus on verapamil. J. Clin.
Hypertension 3:72S-78S, 1986.
54.Varin, F., Cubeddu, L.X. and Powell, J.R. Carvedilol (BM 14190) HPLC analysis and disposition in healthy
volunteers. J. Pharmaceutical Sci. 75:146-149, 1986.
55.Cubeddu, L.X., Hoffmann, I.S., Davila, S., Escontrelas, C., Morales, C. and Rios, A. Effects of propranolol,
clonidine and hydrocholorothiazide treatment and abrupt discontinuation on central and peripheral noradrenergic
activity in essential hypertension. Life Sci. 39:2463-2474, 1986.
56.Varin, F., Cubeddu, L.X. and Powell, J.R. Liquid chromatographic assay and disposition of carvedilol in healthy
volunteers. J. Pharmaceut. Sci. 75:1195-1197, 1986.
57.Cubeddu, L.X., Fuenmayor, N., Varin, F., Villagra, V.G., Colindres, R.E. and Powell, J.R. Clinical pharmacology
of carvedilol in normal volunteers. J. Clin. Pharmacol. Ther. 41:31-44, 1987.
58.James, M.K. and Cubeddu, L.X. Pharmacological characterization and functional role of muscarinic autoreceptors
in the rabbit striatum. J. Pharmacol. Exp. Ther. 240:203-215, 1987.
59.Cubeddu, L.X., Fuenmayor, N., Caplan, N. and Ferry, D. Clinical pharmacology of doxazosin in patients with
essential hypertension. J. Clin. Pharmacol. Ther. 41:439-449, 1987.
60.Diliberto, P.A., Garrett, L., James, M.K. and Cubeddu, L.X. Ionic mechanism of dopaminergic and muscarinic
auto- and heteroreceptor activation in superfused striatal slices: role of extracelllular chloride. J. Pharm. Exp. Ther.
240:795-801, 1987.
61.Cubeddu, L.X. and Parker, E.M. Dopamine intraneuronal pools and mechanisms by which amphetamine increases
dopamine efflux from dopaminergic neurons. Progr Catechol Res. 439-445, 1988.
62.Cubeddu, L.X., Fuenmayor, N., Varin, F., Villagra, V.G., Colindres, R.E. and Powell, J.R. Mechanism of the
vasodilatory effect of carvedilol in normal volunteers: A Comparison with labetalol. J. Cardiovasc. Pharmacol. 10
(Suppl II) 581-584, 1987.
63.Suarez-Roca, H., Lovenberg, T.W. and Cubeddu, L.X. Comparative Dopamine-cholinergic mechanisms in the
olfactory tubercle and the striatum: effects on Metoclopramide. J. Pharm. Exp. Ther. 243:840-851, 1987
64.Light, K.C., Obrist, P.A. and Cubeddu, L.X. Evaluation of the new ambulatory blood pressure monitor
(Accutracker 102): Comparisons with direct arterial pressure, stethoscopic auscultatory pressure, and readings from a
similar monitor (Spacelabs model 5200). Psychophysiology 25(1):107-116, 1988
65.Cubeddu, L.X. New alpha 1 adrenergic receptor antagonists for the treatment of hypertension: Role of vascular
alpha receptors on the control of peripheral resistance. Am. Heart J. 116(1):133-146, 1988.
11

LUIGI X. CUBEDDU
66.Cubeddu, L.X., Pool, J.L., Bloomfield, R., Klotman, P.E., Pickering, B.I., Wombolt, D.G., Nelson, E.B. and
Halperin, A. Effect of doxazosin monotherapy on blood pressure and plasma lipids in patients with essential
hypertension. Amer. J. Hypertension. 1:158-167, 1988
67.Hoffmann, I.S., Talmaciu, R.K., Ferro, C.P. and Cubeddu, L.X. Sustained high release at rapid stimulation rates and
reduced functional autoreceptors characterize prefrontal cortex dopamine terminals. J. Pharm. Exp. Ther. 245: 761-
772, 1988.
68.Zubieta, J.K., Cragoe, E.J. and Cubeddu, L.X. Effects of Amiloride, and 5-(N,N-Hexamethylene) Amiloride on
dopaminergic and acetylcholinergic neurotransmission. J. Pharm. Exp. Ther. 247:88-95, 1988.
69.Parker, E.M. and Cubeddu, L.X. Comparative effects of amphetamine, phenylethylamine and related drugs on
dopamine efflux, dopamine uptake and mazindol binding. J. Pharm. Exp. Ther. 245(1):199-210, 1988.
70.Williams, D.M. and Cubeddu, L.X. Amlodipine pharmacokinetics in healthy volunteers. J. Clin. Pharm. 28:990-
994, 1988.
71.Lovenberg, T.W. and Cubeddu, L.X. Monoamine release by compound 48/80 from non-mast cell compartments in
mouse brain slices. J. Pharm. Exp. Ther. 247(2):562-568, 1988.
72.Diliberto, P.A., Jeffs, R.A. and Cubeddu, L.X. Effects of low extracellular chloride on dopamine release and the
dopamine transporter. J. Pharmacol. Exp. Ther. 248:644-653, 1989.
73.Fuenmayor, N.T., Faggin, B.M. and Cubeddu, L.X. Comparative efficacy, safety, and kinetics of immediate- and
slow-release verapamil in hispanic patients with essential hypertension. J. Cardiovasc. Pharmacol. 13: S53-S56, 1989.
74.Curiel, R., Perez-Gonzalez J., Brito, N., Zerpa R., Tellez D., Cabrera J., Curiel C., and Cubeddu L.X. Positive
inotropic effects mediated by alpha1-adrenoceptors in intact human subjects. J. Cardiovasc. Pharmacol. 14:603-615,
1989.
75.Neidzwiecki, D.M., Cubeddu, L.X. and Mailman, R.B. Comparative antidopaminergic properties of thioridazine,
mesoridazine and sulforidazine on the corpus striatum. J. Pharmacol. Exp. Ther. 250:117-125, 1989.
76.Niedzwiecki, D.M., Cubeddu, L.X. and Mailman, R.B. Comparative anticholinergic properties of thioridazine,
mesoridazine and sulforidazine. J. Pharmacol. Exp. Ther. 250:126-133, 1989.
77.Cubeddu, L.X., Lovenberg, T.W., Hoffmann, I.S. and Talmaciu, R.K. Phorbol Esters and D2-Dopamine Receptors.
J. Pharmacol. Exp. Ther. 251:687-693, 1989.
78.Talmaciu, R.M., Hoffmann, I.S. and Cubeddu, L.X. Differential effects of phorbol ester on prefrontal cortex and
striatal dopamine terminals: dependence on rate and duration of stimulation. J. Pharmacol. Exp. Ther. 251: 1160-1165,
1989.
79.Carl, P.L., Cubeddu, L.X., Lindley, C., Myers, R.D. and Rezvani, A.H. Do humoral factors mediate cancer
chemotherapy-induced emesis? Drug Metabolism Revs. 21:319-333, 1989.
80.Bonnet, J-J, Benmansour, S., Costentin, J., Parker, E.M. and Cubeddu, L.X. Thermodynamic analysis of the binding
of substrates and uptake inhibitors on the neuronal carrier of dopamine labeled with 3H-GBR 12783 or 3H-mazindol. J.
Pharmacol. Exp. Ther. 253: 1206-1215, 1990.
81.Cubeddu, L.X., Hoffmann, I.S., Fuenmayor, N.T. and Finn, A.L. Efficacy of ondansetron and the role of serotonin
in cisplatin-induced nausea and vomiting. N Engl J. Med. 322: 810-816, 1990.
82.Cubeddu, L.X., Lindley, C.M., Wetsler, W., Carl, P.L. and Negro-Vilar, A. Role of angiotensin II and vasopressin
in cisplatin-induced emesis. Life Sci. 46: 699-705, 1990.
12

LUIGI X. CUBEDDU
83.Faggin, B.M., Zubieta, J.K., Rezvani, A.H. and Cubeddu, L.X. Neurotensin-induced dopamine release in vivo and
in vitro from substantia nigra and nucleus caudate. J. Pharmacol. Exp. Ther. 252: 817-825, 1990.
84.Faggin, B.M. and Cubeddu, L.X. Rapid desensitization of dopamine release induced by neurotensin and
neurotensin fragments. J. Pharmacol. Exp. Ther. 253: 812-818, 1990.
85.Cubeddu, L.X., Hoffmann, I.S., Fuenmayor, N.T. and Finn, A.L. Antagonism of serotonin S3 receptors with
ondansetron prevents nausea and emesis induced by cyclophosphamide-containing chemotherapy regimens. J Clin
Oncol 8: 1721-1727, 1990.
86.Cubeddu, L.X., Hoffmann, I.S., Fuenmayor, N.T. and Finn, A.L. Efficacy of ondansetron and the role of serotonin
in cisplatin-induced nausea and vomiting. Letter to the Editor. New England J. of Med. 323: 1991.
87.Cubeddu, L.X., Hoffmann, I.S., Fuenmayor, N.T. and Finn, A.L. Efficacy of ondansetron in cyclophosphamideinduced
nausea and vomiting. Letter to the Editor. J. Clin. Oncol. 1991.
88.Cubeddu, L.X., Hoffmann, I.S., Talmaciu, R.K., Diliberto, P. and Lovenberg, T. Carbachol Phorbol ester
interactions at muscarinic receptors modulating Dopamine release. Neuroscience Lett. 131: 245-248, 1991.
89.Cubeddu, L.X., Hoffmann, I.S., Fuenmayor, N.T. and Malave J. Changes in serotonin metabolism in cancer
patients: its relationships to nausea and vomiting induced by chemotherapeutic drugs. Brit. J. Cancer. 66:198-203,1992.
90.Buckley, J.W., Hedner, T., Masotto, C., Posvar, E., Negro-Vilar, A. and Cubeddu, L.X. Comparative effects of
verapamil on volume overload on atrial natriuretic factors and the renin-angiotensin-aldosterone-vasopressin system. J.
Clin. Pharmacol. 32:1120-1127, 1992.
91.Fuenmayor, N.T., Faggin B.M and Cubeddu L.X. Comparative efficacy, safety and kinetics of verapamil SR and IR
in hypertensive patients. Drugs. 44:Suppl. 1:1-11, 1992.
92. Cubeddu L.X. Mechanisms by which cancer chemotherapeutic drugs induce emesis. Seminars in Oncology. 19:2-
13, 1992.
93. Cubeddu L.X., Hoffmann I.S. and Fuenmayor N.T. Serotonin and Emesis- from animals to humans. Brit J Cancer.
66:suppl XIX:S9-S11, 1992.
94. Cubeddu LX. Receptores serotonérgicos 5-HT3: papel en las náuseas y vómitos asociados a la quimioterapía
antineoplásica. Revista de Farmacología Clinica y Experimental. Special Number. 107-109, 1992.
95. Beck T.M., Cubeddu L.X., Hainsworth J., Hesketh P.J., Bryson J.C., Scarantino C.W. and Berry W.R. Serotoninmediated
emesis: the role of ondansetron. Seminars in Oncology. 19:44-46, 1992.
96. Cubeddu, L.X.,and Hoffmann, I.S. Participation of serotonin on early and delayed emesis induced by initial and
subsequent cycles of cisplatinum-based chemotherapy: effects of dexamethasone and metoclopramide. J Clin
Pharmacol.33: 691-697, 1993.
97. Cubeddu, L.X., Pendergrass,K., Thomas, R., Martin, Y., Burton, G., Meshad, M., Galvin, D. and Ciociola, A.A.
Efficacy of oral ondansetron, a selective antagonist of 5-HT3 receptors, in the treatment of nausea and vomiting
associated with cyclophosphamide-based chemotherapies. Am J Clin Oncol. 17: 137-146, 1994
98. Alfieri B.A. and Cubeddu L.X. Changes in urinary 5-HIAA excretion induced by dietary manipulations in man.
J.Clin. Pharmacol. 34:153-157,1994.
99. Agneter, E., Hoffmann, I.S., Cubeddu, L.X. and Singer, E. Behavior of mesocortical dopamine terminals during
single and repetitive stimulation: comparison with nigrostriatal neurons. J. Pharmacol Exp Ther. 269:470-476;1994.
13

LUIGI X. CUBEDDU
100. Alfieri, A.B. and Cubeddu, L.X. Treatment with para-chlorophenylalanine antagonizes the emetic response and
the serotonin releasing actions of cisplatin, in cancer patients. Brit J Cancer . 71: 629- 632, 1995.
101. Cubeddu L.X., O'Connor D.T. and Parmer R.J. Plasma chromogranin A: a marker of serotonin release and of
emesis associated to cisplatin chemotherapy. J Clin Oncol. 13: 681-687, 1995.
102. Cubeddu L.X., O'Connor D.T., Hoffmann I.S. and Parmer R.J. Plasma chromogranin A markes emesis and
serotonin release associated with dacarbazine and nitrogen mustard, but not with cyclophosphamide-based
chemotherapies. Brit J Cancer. 72: 1033-1038, 1995.
103. Alfieri, A.B. and Cubeddu, LX. Comparative efficacy of a single oral dose of ondansetron and of buspirone
against cisplatin-induced emesis, in cancer patients. Br. J. Cancer. 72: 1013-1015, 1995.
104. DiBenedetto J, Cubeddu LX., Ryan T., Kish J., Sciortino D., Beall C., Eisenberg P., Henderson. C., Griffin D and
Wentz A. Ondansetron for nausea and vomiting associated to moderately emetogenic cancer chemotherapy. Clin Ther.
17: 1091-1098, 1995.
105. Gentry LO, Rodriguez-Gomez G, Pien F, Cubeddu L, Holley HP, Buaron K, Giguere G and Collins JJ.
Comparative effects of ceftazidime two or three times daily in patients with skin and skin structure infections. Am J.
Therapeutics. 3: 212-218, 1996.
106. Cubeddu L.X. Serotonin Mechanisms in chemotherapy-induced Emesis in Cancer Patients. Oncology. 53:18-25,
1996.
107. Hoffmann, I.S., Talmaciu, R.K., Aquino, R and Cubeddu, L.X. Differential effects of muscarinic receptor agonists
and phorbol esters on muscarinic and D2-dopamine release modulatory receptors. J. Pharmacol. Exp. Ther. 278: 662-
668, 1996.
108. Guevara, B.E., Talmaciu RK, Hoffmann, I.S. and Cubeddu, L.X. Comparative dopamine-acetylcholine
interactions in the ventral and dorsal striatum of rabbit and rat brain. Brain Res. 733: 105-107, 1996.
109. Kris M G., Cubeddu LX., Gralla RJ, Cupissol D., Tyson L., Venkatraman E and Homesley HD. Are more
antiemetic trials with placebo necessary? Amer Cancer Soc. 78: 2193-2198, 1996.
110. Guevara, B.E., Talmaciu RK, Hoffmann, I.S. and Cubeddu, L.X. Comparative dopamine-acetylcholine
interactions in the ventral and dorsal striatum of rabbit and rat brain. Brain Res. 733: 105-107, 1996.
111. Guevara B.E., Hoffmann I.S. and Cubeddu L.X. Differential effects of kainic acid on dopamine and
serotonin metabolism in ventral and dorsal striatal regions. Brain Res. 749:139-142,1997.
112. Cubeddu L.X., Trujillo, L.C., Talmaciu I., Gonzalez V, Guariguata J, Seijas J, Miller IA and Paska, W.
Antiemetic activity of ondansetron in acute gastroenteritis. Aliment Pharmacol Ther. 11: 185-191, 1997.
113. Guevara, B.E., Hoffmann, I.S. and Cubeddu, L.X. Ventral and dorsal striatal cholinergic neurons have
different sensitivity to kainic acid. Neurochemistry International 31:723-730. 1997.
114. Fuenmayor N.T., Moreira, E. De los Rios V., Cevallos J.L. and Cubeddu L.X. Relations between insulin,
glucose and dihydroepiandrosterone-sulfate concentrations in obese patients with hypertension: short
term effects of antihypertensives. J Cardiovasc Pharmacol. 30:523-527, 1997.
115. Rodriguez-Plaza L, Alfieri AB and Cubeddu LX. Urinary excretion of nitric oxide metabolites in
runners, sedentary individuals, and patients with coronary artery disease: effects of 42 km marathon, 15
km race and a cardiac rehabilitation program. J Cardiovasc Risk. 4: 367-372, 1997.
14

LUIGI X. CUBEDDU
116. Fuenmayor, N.T., Moreira, E and Cubeddu, L.X. Salt sensitivity and insulin resistance in essential
hypertension. Am. J Hypert. 4:397-402, 1998.
117. Castejon, A.M and Cubeddu, L.X. Level of punishment determines anticonflict activity of ondansetron in
pigeons: comparison with buspirone and diazepam. Pharmacol Biochem Behavior. 61:451-457, 1998.
118. Castejon AM, Paez X, Hernandez L and Cubeddu LX. Use of intravenous microdialysis to monitor
changes in serotonin release and metabolism induced by cisplatin in cancer patients: comparative effects
of granisetron and ondansetron. J Pharmacol Exp Ther. 291(3):960-966, 1999.
119. Cubeddu LX, Bonisch H, Gothert M, Molderings G, Racke K, Ramadori G, Miller KJ, Schworer H.
Effects of metformin on intestinal 5-hydroxytryptamine (5-HT) release and on 5-HT3 receptors. Naunyn
Schmiedebergs Arch Pharmacol. 361(1):85-91, 2000.
120. Ischia R, Gasser RW, Fischer-Colbrie R, Eder U, Pagani A, Cubeddu LX, Lovisetti-Scamihorn P,
Finkenstedt G, Laslop A, Winkler H. Levels and molecular properties of secretoneurin-immunoreactivity
in the serum and urine of control and neuroendocrine tumor patients. J Clin Endocrinol Metab. 85(1):355-
360, 2000.
121. Alfieri A.B. and Cubeddu L.X. Role of NK1 receptors on cisplatin-induced nephrotoxicity in the rat.
Naunyn Schmiedeberg’s Arch Pharmacol .361(3):334-338, 2000.
122. Cubeddu LX, Alfieri AB, Hoffmann IS, Jimenez E, Roa MC, Cubeddu RC. Nitric oxide and salt
sensitivity. Am J Hypertens. 13:973-979, 2000.
123. Cubeddu LX, Hoffmann IS, Jimenez E, Roa CM, Cubeddu RJ, Palermo C and Baldonedo RM. Insulin
and blood pressure responses to changes in salt intake. J Human Hypertens. 14:S32-S35, 2000.
124. Alfieri A.B., Rodriguez-Plaza L and Cubeddu L.X. Effects of short- and long-term exercise on urinary
cGMP excretion in healthy subjects and in patients with coronary artery disease. J Cardiovasc Pharmacol
35:891-896, 2000.
125. Alfieri A.B. and Cubeddu L.X. Role of NK1 receptors and nitric oxide on cyclophosphamide-induced
bladder toxicity . J Pharmacol Exp Ther. 295:824-829, 2000.
126. Alfieri AB, Malave A and Cubeddu LX: Nitric oxide synthases and cyclophosphamide-induced cystitis in
rats.
Naunyn Schmiedebergs Arch Pharmacol. 363(3):353-357, 2001.
127. Xu X, Cubeddu LX and Malave A. Expression of inducible nitric oxide synthase in primary culture of the rat
bladder smooth muscle by plasma from cyclophosphamide-treated rats. Eur J Pharmacol. 416:1-9, 2001.
128. Hoffmann, IS, Jimenez E and Cubeddu LX. Urinary albumin excretion in lean, overweight and obese
glucose tolerant individuals: its relationship with dyslipidemia, hyperinsulinemia and blood pressure. J
Human Hyperten. 15:407-412, 2001.
129. Hoffmann IS, Guevara BH and Cubeddu LX. Potassium, Muscarinic M3 receptors and dopamine release.
Neurosci Res Comm. Brain Res. 29:1530,2001.
130. Hoffmann IS and Cubeddu LX. Clustering of silent cardiovascular risk factors in apparently healthy
Hispanics.
J Hum Hypertens. 16 Suppl 1:S137-141, 2002.
15

LUIGI X. CUBEDDU
131. Ana M Castejon, Irene S. Hoffmann, Jimenez E, Cubeddu RJ, Baldonedo RM, and Luigi X. Cubeddu.
Differential blood pressure effects of oral glucose and intravenous l-arginine in healthy lean normotensive
and obese hypertensive subjects. J Human Hypertens. 16 Suppl 1:S133-136, 2002.
132. Cubeddu LX and Hoffmann IS. Insulin resistance and upper-normal glucose levels in hypertension: a
review.
J Hum Hypertens. 16 Suppl 1:S52-55, 2002.
133. Heberto Suarez-Roca and Luigi X. Cubeddu. The selective serotonin reuptake inhibitor citalopram,
induces the storage of serotonin in cathecolaminergic terminals. J Pharmacology Exp Ther. 302: 174-179,
2002.
134. GuevaraBH, Torrico F, Hoffmann IS and Cubeddu LX. Lesion of caudate-putamen interneurons with
kainic acid alters dopamine and serotonin metabolism in the olfactory tubercle of the rat. Cell Mol
Neurobiol. 22: 835-844, 2002.
135. Guevara BH, Cespedes GC and Cubeddu LX. Treatment with 7-nitroindazole enhances kainic acid
induced cholinergic neurotoxicity in the rat striatum: a neuroprotective role for neuronal nitric oxide. Cell
Mol Neurobiol. 22:827-834, 2002.
136. Luigi X. Cubeddu , Irene S. Hoffmann, Lisette M Aponte; Rosaura Nuñez- Bogesits, Helimenia Medina-
Suniaga, Magaly Roa and Robert S. Garcia. Role of salt sensitivity, blood pressure, and hyperinsulinemia
in determining high upper normal levels of urinary albumin excretion in a healthy adult population.
Am J Hypertens. May;16(5):343-349, 2003.
137. Castejon AM, Alfieri AB, Hoffmann IS, Rathinavelu A and Cubeddu LX. Alpha-adducin polymorphism,
salt sensitivity, nitric oxide excretion and cardiovascular risk factors in Hispanics. Am J Hypertens. 2003
Dec;16(12):1018-24.
138. Luigi X. Cubeddu. QT prolongation and fatal arrhythmias: a review of clinical implications and effects of
drugs. Am J Therapeutics. 2003 Nov-Dec;10(6):452-7.
139. Hoffmann IS, Roa M, Torrico F and Cubeddu LX. Ondansetron and metformin-induced side effects.
Am J Therapeutics. 2003 Nov-Dec;10(6):447-51.
140. Ganapathipillai S, Laval G, Hoffmann IS, Castejon AM, Nicod J, Dick B, Frey FJ, Frey BM, Cubeddu
LX, Ferrari P CYP11B2-CYP11B1 haplotypes associated with decreased 11{beta}-hydroxylase activity. J
Clin Endocrinol Metab. 2005; Feb 90:1220-1225.
141. Hoffmann, IS, Tavares Mordwinkin R, Castejon AM, Alfieri AB and Cubeddu LX. Endothelial nitric
oxide synthase polymorphism, nitric oxide production, salt sensitivity and cardiovascular risk factors in
Hispanics. J. Human Hypertens 2005 Mar;19(3):233-40.
142. Seamon M and Cubeddu LX. Statin Withdrawal: Clinical implications and molecular mechanisms.
Pharmacotherapy. 2006 Sep;26(9):1288-1296.
143. Castejon AM, Bracero J, Hoffmann IS and Cubeddu LX. NAD(P)H oxidase p22phox gene C242T
polymorphism, nitric oxide production, salt sensitivity and cardiovascular risk factors in Hispanics.
J Hum Hypertens. 2006 Oct;20(10):772-9. Epub 2006 Jun 1.
144. Cubeddu LX, Cubeddu RJ, Heimowitz T, Restrepo B, Lamas GA and Weinberg GB. Comparative lipidlowering
effects of policosanol and atorvastatin: a randomized, parallel, double-blind, placebo-controlled
trial. Am Heart J. 2006 Nov;152(5):982.e1-5.
16

LUIGI X. CUBEDDU
145. Tristano A, Castejon AM, Castro A and Cubeddu LX. “Effects of statin treatment and withdrawal on
Angiotensin II-induced phosphorylation of p38 MAPK and ERK1/2 in Cultured Vascular Smooth Muscle
Cells. Biochem Biophys Res Commun. 2007 Feb 2;353(1):11-17. Epub 2006 Nov 17.
146. Hoffmann IS and Cubeddu LX. Increased blood pressure reactivity to dietary salt in patients with the
metabolic syndrome. J Hum Hypertens. 2007 Jun;21(6):438-44. Epub 2007 Feb 1
147. Hoffmann IS, Alfieri AB, Cubeddu LX. Effects of lifestyle changes and metformin on salt sensitivity and
nitric oxide metabolism in obese salt-sensitive Hispanics. J Hum Hypertens. 2007 Jul;21(7):571-8. Epub
2007 Apr 26.
148. Castejon AM, Tristano AG, Cubeddu LX. Upregulation of angiotensin II AT-1 R following statin
withdrawal. J Cardiovasc Pharmacol. 2007 Dec;50(6):708-11.
149. Cubedu LX, Alfieri AB, Hoffmann IS. Lowering the threshold for defining microalbuminuria: effects of
lifestyle-metformin intervention in overweight-obese, “normoalbuminuric” non-diabetic subjects. Am J
Hypertens. 2008 Jan;21(1):105-110.
150. Hoffmann IS, Alfieri AB, Cubeddu LX. Salt resistant and salt sensitive phenotypes determine the
sensitivity of blood pressure to weight loss in overweight/obese subjects. J Clin Hypertens (Greenwich).
2008 May; 10 (5):355-360.
151. Hoffmann IS and Cubeddu LX. Salt and the Metabolic Syndrome. Nutr Metab Cardiovasc Dis. 2009
Feb;19(2):123-128. Epub 2008 Jun 16.
152. Zamora CR and Cubeddu LX. Microalbuminuria: do we need a new threshold? J Hum Hypertens. 2009
Feb; 23(2):146-149.
153. Cubeddu LX. Salt, Salt Sensitivity and the Metabolic Syndrome. Medscape. 2009; Feb 23,
http://www.theheart.org/article/942057.do#comments
154. Alfieri A., Hoffmann IS, Roa CM and Cubeddu LX. Alteraciones en la actividad biológica del oxido
nítrico asociadas con la hipertensión sensible al sodio y con la obesidad. Latin-American Journal of
Hipertensión. 3: #7, 206-210, 2009.
155. Cubeddu LX. Iatrogenic QT Abnormalities and Fatal Arrhythmias: Mechanisms and Clinical
Significance. Curr Cardiol Rev, 2009; 5(3):166-76.
156. Calderon RA, Cubeddu LX., Goldberg RB, Schiff ER. Statins in the presence of dyslipidemia in the
presence of elevated liver aminotransferases: a therapeutic dilemma. Mayo Clin Proc; 2010; 85:349-356.
157. Cubeddu LX and Hoffmann IS. One-hour postload plasma glucose levels, a predictor of additional risk
for diabetes: prevalence, mechanisms and associated cardiovascular risk factors in Hispanics. Metabolic
Syndrome and Related Disorders. 2010 Oct;8(5):395-402.
158. Pineda A. and Cubeddu LX. Statin Rebound or Withdrawal Syndrome: Does it exist? Curr Atheros Rev.
Curr Atheroscler Rep. 2011 Feb; 13(1):23-30.
159. Irene S Hoffmann, Anna B. Alfieri, and Luigi X. Cubeddu . Prevalence of glucose abnormalities and
diagnostic value of fasting glucose and fasting insulin in Urban Hispanics. Am J Ther. In Press.
160. Hoffmann IS and Cubeddu LX. Association of Glucose Abnormalities with Traits of Metabolic
Syndrome. Am J Ther. In Press.
17

LUIGI X. CUBEDDU
161. Cubeddu LX and Hoffmann IS. Metabolic syndrome: an all or none or a continuum load
of risk. Metabolic Syndromes and Related Syndromes. Metab Syndr Relat Disord. 2012
Feb;10(1):14-9. Epub 2011 Oct 27.
18

LUIGI X. CUBEDDU
PRESENTATIONS AT SCIENTIFIC MEETTINGS.
1. Cubeddu, L.X., Pluchino, S., and Pinardi, G. Glucagon y sistema adrenergico en estructura marcapaso de rata.
Convencion Anual de ASOVAC, 1971. Acta Cientifica Venezolana. 22:31, 1971.
2. Cubeddu, L.X., Castaneda M.L. and Pluchino S. Receptores adrenergicos en el utero aislado de rata. Convencion
Anual de ASOVAC, 1971. Acta Cientifica Venezolana. 22:32, 1971.
3. Cubeddu, L.X., Castaneda M.L. and Pluchino S. Mecanismo de accion de la 5-hidroxitriptamina en el utero aislado
de rata. Convencion Anual de ASOVAC, 1971. Acta Cientifica Venezolana. 22:32, 1971.
4. Cubeddu, L.X. The uptake and metabolism of l-3H-norepinephrine in the perfused cat spleen. Seminario dictado en
la Universidad de Colorado Medical Center, USA., 28/12/71.
5. Cubeddu, L.X. and Weiner, N. The effect of methylguanidine on the uptake and metabolism of l-3H-norepinephrine
in the isolated and perfused cat spleen. Proc. Fifth International Congress in Pharmacology, San Francisco, California;
p 49, 1972.
6. Pluchino S., Cubeddu L.X. and Castaneda, ML. Effect of catecholamines in the isolated rat uterus. Proc. Fifth Intern.
Cong. Pharmacol., p 184, 1972.
7. Cubeddu, L.X., Weiner, N. and Langer, S.Z. Effect of phentolamine and cocaine, on the uptake, release and
metabolism of norepinephrine. Neurochemistry Meeting. Columbus Ohio February, 1973.
8. Cubeddu, L.X., Barnes, E., Weiner, N. Regulation of transmitter by nerve stimulation. The role of alpha receptors.
Fall Pharmacology Meeting, ASPET, Oct. 1973.
9. Cubeddu, L.X. The role of alpha receptors and neuronal uptake in regulating transmitter release and metabolism.
Seminario dictado en la Universidad de Colorado. Medical Center. USA, 1973.
10. Cubeddu, L.X. Regulation of norepinephrine release by nerve stimulation: Role of alpha presynaptic receptors,
cyclic AMP and Prostaglandins. Seminario dictado en la Universidad de Colorado Medical Center. USA, 1974.
11. Cubeddu, L.X., Barnes, E., Weiner, N. Regulation of transmitter release by nerve stimulation. A possible role for
cyclic AMP. Federations of American Society for Experimental Biology, 1974.
12. Cubeddu, L.X., Weiner, N. Relationship between a granular effect and exocitotic release of norepinephrine by
nerve stimulation. Fall Pharmacology Meeting. ASPET, 1974.
13. Cubeddu, L.X. A novel mechanism for the regulation of nerepinephrine release by nerve stimulation. Seminario
dictado en la Universidad de Colorado. En el Cardiovascular Pulmonary Research Laboratory, 1974.
14. Cubeddu, L.X. Regulation of exocytotic release of norepinephrine by nerve stimulation. Seminario dictado en la
Universidad de Missisippi, Medical Center, USA, 1974.
15. Cubeddu, L.X. Efectos del AMP ciclico sobre la liberacion de norepinefrina (NE) y dopamina-beta-hidroxilasa
(DBH) por estimulacion nerviosa. ASOVAC. Maracaibo 1974, XXIV Convencion Anual. Acta Cient. Venezol. 25:25,
1974.
16. Cubeddu, L.X. Metabolismo de la norepinefrina tritiada (3H-NE) liberada espontaneamente o por estimulo
nervioso, en el bazo aislado y perfundido del gato. ASOVAC. Maracaibo 1974, XXIV Convencion Anual. Acta
Cientif. Venezol. 25:26, 1974.
17. Cubeddu, L.X. Regulacion de la liberacion de norepinefrina. Papel del AMP ciclico. Charla Conferencia dictada en
el Hospital "Antonio M. Pineda" Universidad de Caracas, 1975.
19

LUIGI X. CUBEDDU
18. Cubeddu, L.X. Neurotransmisores a nivel central: Norepinefrina, dopamina y serotonina. Curso de Psiquiatria.
Hospital Universitario de Caracas, 1975.
19. Cubeddu, L.X. Ponente invitado a las "Gordon Research Conferences on catecholamines". Presentacion: "Release
of norepinephrine and dopamine- beta-hydroxylase by nerve stimulation Regulatory mechanisms". Andover, New
Hampshire, 1975.
20. Cubeddu, L.X. and Weiner, N. Alpha presynaptic regulation of norepinephrine and dopamine-beta-hydroxylase
release by nerve stimulation. Helsinky, Finlandia, 1975.
21. Cubeddu, L.X. and Goldstein, D.J. Efecto inhibitorio del liquido cefalorraquideo humano sobre la feniletanolamina
n-metil transferasa (PNMT) ASOVAC. Caracas 1975. XXV Convencion anual. Acta Cient. Venezol. 26:36, 1975.
22. Cubeddu, L.X. Es el efecto de la papaverina sobre la neurotransmision adrenergica mediado por el AMP ciclico?
Asociacion Venezolana para el Avance de la Ciencia, ASOVAC. Caracas, 1975, XXV Convencion Anual.
23. Cubeddu, L.X. Mecanismos por los cuales la fenoxibenzamina aumenta el eflujo de norepinefrina inducido por la
estimulacion nerviosa. Asociacion venezolana para el Avance de la Ciencia ASOVAC, Caracas, 1975, XXV
Convencion Anual.
24. Cubeddu, L.X. and Goldstein, D.J. Actividad dopamina-beta-hidroxilasa en el liquido cefalorraquideo humano.
Asociacion Venezolana para el Avance de la Ciencia ASOVAC, Caracas, 1975. XXV Convencion Anual.
25. Goldstein, D.J., Cubeddu, L.X., Davila, J. and Klahr, L. Actividad DBH en el liquido cefalorraquideo de
hipertensos esenciales. Asociacion Venezolana para el Avance de la Ciencia ASOVAC, Caracas, 1975. XXV Congreso
Anual.
26. Cubeddu, L.X. Ponente Curso "Cancer quimico Experimental". Tema: Induccion Enzimatica y carcinogenisis
quimica. Universidad Central de Venezuela. Facultad de Farmacia, 1975.
27. Cubeddu, L.X. Efectos compuestos de accion granular sobre la liberacion de norepinefrina y dopamina-betahidroxilasa.
Primera Reunion Cientifica Regional Panama, 1976.
28. Gimenez, M., Cubeddu, L.X. Efecto inhibitorio del NaCl sobre la feniletanolamina-N-metil-transferasa (PNMT)
Primera Reunion Cientifica Regional. Panama, 1976.
29. Cubeddu, L.X. Charla dictada al Curso "Introduccion a la neuroquimica". Titulo: Neurotransmision adrenergica y
dopaminergica central y periferica". Instituto Venezolano de Investigaciones Cientificas (IVIC), 1976.
30. Cubeddu, L.X., Talmaciu, R., Davila, J., Klahr, L. and Goldstein, D. Dopamina-beta-hidroxilasa en liquido
cefalorraquideo y plasma de pacientes normotensos e hipertensos esenciales fijos. Primer Simposio Internacional sobre
Hipertension Arterial. 1-3 sept., 1976. Caracas.
31. Pinardi, G., Cubeddu, L.X., Santiago, E. and Talmaciu, R. /actividad dopamina-beta-hidroxilasa plasmatica en
perros sometidos a shock hemorragico. VI Congreso Latinoamericano de Farmacologia 2-9 dias dic., 1976. Buenos
Aires, Argentina.
32. Talmaciu, R., Santiago, E., Cubeddu, L.X. and Pinardi, G. Efectos de lahemorragia sobre los niveles plasmaticos de
dopamina-beta-hidroxilasa y catecolaminas. VI Congreso Latinoamericano de Farmacologia. 2-9 dic., 1976,Buenos
Aires, Argentina.
33. Cubeddu, L.X. Conferencia dictada en el VI Congreso Latinoamericano de Farmacologia. 2-9 dic., 1976. Buenos
Aires, Argentina.
20

LUIGI X. CUBEDDU
34. Cubeddu, L.X. Metabolim of 3H-dopamina in the rat caudate putamen nucleus: Selective increase in 3H-DOPAC
release by a reserpin like agent. VI Int. Meeting of Int. Soc. Neurochem. 21-26 agosto, 1977. Copenhegen Denmark.
35. Cubeddu, L.X. Seminario dictado agosto 16, 1977 en la Universidad de North Caroline at Chapel Hill
Departamento de Farmacologia. Escuela de Medicina. Titulo: Changes in plasma dopamina beta hydroxylase and
catecholamines induce by hemorrhagic hypotension and blood reinfusion, in dogs.
36. Cubeddu, L.X. Seminario dictado agosto 18, 1977 en la Universidad de North Caroline at Chapel Hill
Departamento de Farmacologia. Escuela de Medicina. Titulo: Metabolism of 3H-dopamine in the neostriatum: A
selective intraneuronal formation of 3h-DOPAC.
37. Cubeddu, L.X. Seminario dictado agosto 19, 1977 en la Division of special mental Health research. NIMH, St.
Elizabeth Hospital. Titulo: Adrenal origin of the changes in plasma DBH and CA induced by hemorrhagic hypotension
in dogs.
38. Ferrari, G., Hoffmann, I.S. and Cubeddu, L.X. Metabolismo de la dopamina tritiada en el nucleo estriado de la rata.
Asociacion Venezolana para el Avance de la Ciencia ASOVAC, Valencia, 1977. XXVII Convencion Anual.
39. Hoffmann, I.S., Ferrari, G.B. and Cubeddu, L.X. Un nuevo metodo para la separacion de la dopamina y sus
metabolitos. Asociacion Venezolana para el Avance de la Ciencia ASOVAC, Valencia, 1977. XXVII Convencion
Anual.
40. Ferrari, G.B., Hoffmann, I.S. and Cubeddu, L.X. Aumento selectivo del DOPAC-H3 por un agente reserpinososimilar.
Asociacion Venezolana para el Avance de la Ciencia. ASOVAC, Valencia, 1977. XXVII Convencion Anual.
41. Cubeddu, L.X. Metabolismo de las catecolaminas y enfermedades neurologicas. Conferencia ASOVAC 1977,
Valencia. XXVII Convencion Anual.
42. Cubeddu, L.X., Talmaciu, R., Santiago, E. and Pinardi, G. Adrenal origin of the increase in plasma dopamine-betahudroxilase
activity and catecholamines induced by hermorrhagic hypotension in dogs. Fall Pharmacology Meeting
ASPET, 1977.
43. Hoffmann, I.S. and Cubeddu, L.X. Metabolism of spontaneously and neurally released 3H-DA from rat neostriatal
tissue 7th int. Cong. Pharmacol. Paris 16-21, Julio, 1978.
44. Barbella, Y.R., Marrero, A., Israel, S.A., Trifaro, J.M. and Cubeddu, L.X. Circulating dopamine-beta-hydroxylase
(DBH) and catecholamines (CA) in dog, rat, and guinea-pig, during hemorrhage and hypoglicemia. 7th Int. Cong
Pharmacol. Paris 16-21, julio, 1978.
45. Cubeddu, L.X., Talmaciu, R., Pinardi, G. and Cubeddu, L.X. Arterial, venous and lymph dopamine-betahydroxylase
(DBH) and catecolamines (CA) during hemorrhagic hypotension in dogs, 7th Int. Cong. Pharmacol. Paris
16-21, julio, 1978.
46. Talmaciu, R., Santiago, E., Pinardi, G. and Cubeddu, L.X. Plasma dopamine-beta-hydroxylase (DBH) and
catecholamines (CA) levels in hemorrhagic hypotension (H-H). A role for the adrenal medulla. 7th Int. Cong.
Pharmacol. Paris 16-21, julio 1978.
47. Pinardi, G., Cubeddu, L.X., Vasquez, J.V. and Talmaciu, R. Chance in dopamine-beta-hydroxylase output inthe left
adrenal vein and thoracic-duct lymph, induced by stimulation of the left splachnic nerve. 7th In. Cong. Pharmacol.
Paris 16-21, julio 1978.
48. Cubeddu, L.X., Hoffmann, I,S. and Paris, V. Effects of phosphodiesterase inhibitors and cyclic AMP on NE and
DA release. Presynaptic Receptors. A Satellite Symposio 22-23, julio, 1978.
21

LUIGI X. CUBEDDU
49. Cubeddu, L.X. Dopamine-beta-hydroxylase of plasma and cerebrospinal fluid, in animal stress and human
hypertension IV. Int. Catecholamine Symposium, sept. 17-22,. Asilomar. California, U.S.A., 1978.
50. Cubeddu, L.X. Invited Speaker : Seminar given on september 27, 1978 at the University of Colorado. Med.
Center. Title: Plasma and CSF Dopamine-beta-hydroxylase activity in animal stress and human essential
hypertension.
51. Hoffmann, I.S., Paris, V. and Cubeddu, L.X. Papaverina, AMP ciclico y liberacion de DA ASOVAC, Maracay,
noviembre 12-17, 1978. XXVIII Convencion Anual.
52. Marrero, A., Israel, A., Barbella, Y.R. and Cubeddu, L.X. DBH plasmatica en hemorragia e hipoglicemia
ASOVAC. Maracay, noviembre 12-17, 1978. XXVIII Convencion Anual.
53. Talmaciu, R., Santiago, E., Pinardi, G. and Cubeddu, L.X. Origen de la dopamina-beta-hidroxylasa (DBH) y
catecolaminas (CA) en hipotension hemorragica experimental ASOVAC, Maracay, noviembre 12-17, 1978. XXVIII
Convencion Anual.
54. Valdivieso, L.H., Blanco, M., Barbella, Y.R., Cubeddu, L.X. and Trifaro, J.M. Cambios opuestos en la dopaminabeta-hydroxilasa
(DBH) y catecolaminas (CA) en feocromocitomas. ASOVAC, Maracay, noviembre 12-17, 1978.
XXVIII Convencion Anual.
55. Israel, A., Talmaciu, R., Vasquez, E., Cubeddu, L.X. and Pinardi, G. Efectos de la estimulacion esplacnica sobre la
concentracion de la dopamina-beta-hidroxylasa (DBH) y catecolaminas (CA) en la vena lumbo adrenal izquierda y el
conducto toracico. ASOVAC, Maracay, noviembre 12-17, 1978. XXVIII Convencion Anual.
56. Barbella, Y.R., Israel, A., Marrero, A., Trifaro, J.M. and Cubeddu, L.X. Relacion entre la dopamina-betahidroxylasa
(DBH) circulante y soluble adrenal ASOVAC, Maracay, noviembre 12-17, 1978. XXVIII Convencion
Anual.
57. Cubeddu, L.X. Papel de la adrenalina Central en la Hipertension Arterial. Conferencia. En patogenia de la
Hipertension Arterial. III Congreso Venezolano de Cardiologia y IX Congreso Suramericano de Cardiologia. Caracas
5-10-79.
58. Hoffmann, I.S. and Cubeddu, L.X. Es la liberacion depamina regulada via receptores presinapticos? ASOVAC,
Barquisimeto, noviembre, 1979. XXIX.
59. Cubeddu, L.X., Blanco, M.C., Valdivieso, L.H., Barbella, Y.R., Klahr, L., Israel, A. and Gonzalez, A.
Feocromocitoma: Heterogeneidad clinica y bioquimica. III Congreso Venezolano de Cardiologia y IX Congreso
Suramericano de Cardiologia, 4-10-79, Caracas.
60. Barbella, Y.R., Davila, J., Zschaeck, D., Ordaz, P., Dominguez, J. and Cubeddu, L.X. Dopamina beta hidroxilasa
en plasma y liquido cefalorraquideo y permeabilidad hematorraquidea a proteinas en hipertension humana. III
Congreso Venezolano de Cardiologia y IX Congreso Suramericano de Cardiologia, 4-10-79, Caracas.
61. Cubeddu, L.X. Mecanismos adrenergicos centrales y presion arterial. Conferencia ASOVAC, Barquisimeto 27-11-
79, Caracas.
62. Cubeddu, L.X. and Goldstein, D.J. Baja actividad dopamina-beta-hidroxilasa (DBH) en el liquido cefalorraquideo
de pacientes hipertensos esenciales. Simposio Internacional sobre los mecanismos centrales en Hipertension. Houston,
Texas, USA, mayo 1980. XXX Convencion Anual.
63. Cubeddu, L.X. and Hoffmann, I.S. Tetrahidropapaverolina (THP) y liberacion de dopamina. ASOVAC Merida,
noviembre, 1980. XXX Convencion Anual.
22

LUIGI X. CUBEDDU
64. Hoffmann, I.S. and Cubeddu, L.X. Efectos de las 2-aminotetralinas sobre la monoamino oxidasa y la liberacionde
dopamina. ASOVAC, Merida, noviembre 1980. XXX Convencion anual.
65. Cubeddu, L.X. Indicadores dela Actividad noradrenergica Central. Conferencia Magistral ASOVAC, Merida 1980.
XXX Convencion Anual.
66. Cubeddu, L.X., Barbella, Y.R., Valdivieso, L.H., Stern, A. and Marrero, A. Plasma dopamine-beta-hydroxylase in
stress and pheochromocytoma. Proc. 4th Meeting on adrenergi mechanims. Porto, sept. 29, oct. 1, 1980.
67. Cubeddu, L.X. and Hoffmann, I.S.: Effects of duration and rate of stimulation on the negative feedback regulation
of dopamine release. Soc. for Neuroscience, 1982.
68. Cubeddu, L.X., Cloutier, G., Harden, T.K., Tanner, L., Gross, K., Rogers, J.F. and Knowlton, G.: Clonidine
interaction with antidepressants: Bupropion vs. imipramine. II World Conference on Clinical Pharmacology and
Therapeutics, August 1983.
69. Cubeddu, L.X., Hoffmann, I.S. and James, M.K.: Effects of benztropine, bupropion, cocaine and nomifensine on
dopamine and acetylcholine release from the rabbit striatum. Soc. for Neuroscience, 1983.
70. James, M.K. and Cubeddu, L.X.: Frequency dependent effects of muscarinic receptor stimulation on striatal
dopamine and acetylcholine release. Soc. for Neuroscience, 1983.
71. Niedzwiecki, D.M., Cubeddu, L.X. and Mailman, R.B.: Thioridazine metabolites are more potent than thioridazine
in regulating neurotransmitter release from striatal slices. Soc. for Neuroscience, 1983.
72. Cubeddu, L.X., Simpson, R.J., Rogers, J.F., Gross, K.M. and Halperin, A.K.: Verapamil (V) and propranolol (P) in
essential hypertension (EHT). Amer. Soc. for Clinical Pharmacology and Therapeutics, March 1984.
73. Cubeddu, L.X., Carr, M. and Fuenmayor, N.: Comparative beta blocking potencies of propranolol and labetalol in
normal volunteers. Labetalol Update: A Clinical Forum. Isle of Palms, South Carolina, Sept. 1984.
74. Cubeddu, L.X., Dubocovich, M.L., Weiner, N., Tepper, J. and Bannon, M.J.: Symposium. Autoreceptors and
Modulation of Neurotransmitter Release. Soc. for Neuroscience, 1984.
75. Cubeddu, L.X., Halperin, A.K., Webb, K.G. and Rogers, J.F.: Comparative effects of verapamil and propranolol in
essential hypertension. Amer. Soc. for Clinical Pharmacology and Therapeutics, March 1985.
76. Carr, M.E., Fuenmayor, N. and Cubeddu, L.X.: Comparative beta blocking potencies of oral propranolol and
labetalol in normal volunteers. Amer. Federation for Clinical Research, May 1985.
77. Cubeddu, L.X.: Calcium channel blockers as monotherapy in hypertension. Symposium on the Current Status of
Calcium Channel Blockers in Hypertension. Southampton, Bermuda, July 1985.
78. James, M.K. and Cubeddu, L.X.: Pharmacological characterization of muscarinic receptors regulating 3H-ACh
release from rabbit striatum. Amer. Soc. for Pharmacology and Experimental Therapeutics, August 1985.
79. Cubeddu, L.X.: Antihypertensive efficacy of verapamil in black and white patients with essential hypertension.
Symposium on A New Era in Hypertension Management: Calcium Antagonists. Puerto Vallarta, Mexico, Sept. 1985.
80. Cubeddu, L.X.: Comparative effects of verapamil and propranolol in hypertension. Symposium on Hypertension -
The Next Decade: Verapamil in Focus. Berlin, West Germany, Oct. 1985.
81. Cubeddu, L.X.: Acute and chronic studies on the antihypertensive effect of verapamil and other calcium channel
blockers. Verapamil Conference. Phoenix, Arizona, Nov. 1985.
23

LUIGI X. CUBEDDU
82. Parker, E.M. and Cubeddu, L.X.: D-amphetamine (A)-induced dopamine (DA) release is not strictly dependent on
newly-synthesized transmitter. FASEB, April 1986.
83. Cubeddu, L.X. and Fuenmayor, N.: Naloxone does not affect blood pressure or plasma catecholamines in patients
with essential hypertension. Amer. Soc. of Hypertension, May 1986.
84. Cubeddu, L.X., Fuenmayor, N., Ferry, D.G. and Caplan, N.: Clinical pharmacokinetics of doxazosin in patients
with essential hypertension. Amer. Soc. of Hypertension, May 1986.
85. Cubeddu, L.X., Fuenmayor, N., Varin, F. and Powell, J.R.: Mechanisms of blood pressure lowering effects of
carvedilol. Amer. Soc. of Hypertension, May 1986.
86. Cubeddu, L.X., Aranda, J., Singh, B., Klein, M., Brachfeld, J., Freis, E., Roman, J. and Eades, T.: Verapamil vs.
propranolol monotherapy in essential hypertension: A multicenter study. Amer. Soc. of Hypertension, May 1986.
87. Cubeddu, L.X. and Hoffmann, I.S.: Comparative effects of clonidine, propranolol and hydrochlorothiazide.
Treatments and withdrawal on peripheral and central catecholamines in essential hypertension. Amer. Soc. of
Hypertension, May 1986.
88. Cubeddu, L.X., Fuenmayor, N., Varin, F., Villagra, V., Colindres, R. and Powell, J.R.: Mechanism of the
vasodilatory effect of carvedilol in normal volunteers: A comparison with labetalol. Int. Soc. of Hypertension, Aug.
1986.
89. Cubeddu, L.X. and Hoffmann, I.S.: Cerebrospinal fluid norepinephrine levels in essential hypertension: Effects of
drug treatment and withdrawal. Int. Soc. of Hypertension, Aug. 1986.
90. Powell, J.R., Lahey, A., Villagra, V.G. and Cubeddu, L.X.: Carvedilol pharmacokinetics after two intravenous
doses. Int. Soc. of Hypertension, Aug. 1986.
91. Diliberto, P.A. and Cubeddu, L.X.: The effects of chloride substitution on spontaneous dopamine efflux and
electrically-evoked release of dopamine and acetylcholine in superfused striatal slices. Soc. for Neuroscience, Nov.
1986.
92. Cubeddu, L.X. and Diliberto, P.A.: The effect of chloride substitution on agonist induced autoreceptor activation in
superfused striatal slices. Soc. for Neuroscience, Nov., 1986.
93. Parker, E.M. and Cubeddu, L.X.: The effect of dopamine (DA) synthesis inhibition on dopaminergic
neurotransmission in rabbit striatal slices. Soc. for Neuroscience, Nov. 1986.
94. Talmaciu, R.K., Hoffmann, I.S. and Cubeddu, L.X.: Dopamine release from rabbit prefrontal cortex is modulated
by D2 dopamine autoreceptors. Soc. for Neuroscience, Nov. 1986.
95. Cubeddu, L.X.: New alpha blocking agents. Am. College of Clin. Pharmacol., Oct. 1986, Main Lecture.
96. Fuenmayor, N. and Cubeddu, L.X.: Comparative pharmacodynamics and kinetics of slow-release (SR) and
immediate release (IR) verapamil under fed and fasting states in essential hypertension. Amer. Soc. Hypert., May
1987.
97. Zubieta, J.K. and Cubeddu, L.X.: Effects of amiloride on dopaminergic and cholinergic mechanisms. Amer. Soc.
Hypert., May 1987.
98. Cubeddu, L.X., Pool, J.L., Bloomfield, R., Pickering, B.I., Klotman, P.E., Wombolt, D.G., Halperin, A. and Nelson,
E.B.: Once a day doxazosin monotherapy for the treatment of essential hypertension: effects of serum lipids. Amer.
Soc. Hypert., May 1987.
24

LUIGI X. CUBEDDU
99. Hoffmann, I.S., Ferro, C.P., Talmaciu, R.K. and Cubeddu, L.X.: Modulation of dopamine release from
mesocortical neurons. Int. and Amer. Soc. Neurochemistry, June 1987.
100. Cubeddu, L.X., Hoffmann, I.S., Suarez-Roca, H., Talmaciu, R.K. and Lovenberg, T.: Acetylcholine release as a
marker for postsynaptic dopamine effects in striatal, limbic and prefrontal regions. Int. and Amer. Soc.
Neurochemistry, June 1987.
101. Diliberto, P.A., and Cubeddu L.X.: Non-vesicular release of dopamine from uperfused striatal slices is induced by
low chloride medium with subsequent inhibition of electrically stimulated acetylcholine and dopamine release. Int. and
Amer. Soc. Neurochemistry, June 1987.
102. Cubeddu, L.X.: Indirect effects of amphetamine and related amines on dopaminergic neurons: ionic mechanisms.
6th Int. Catecholamine Sym., June 1987.
103. Cubeddu, L.X. and Parker, E.M.: Dopamine intraneuronal pools and mechanisms by which amphetamine
increases dopamine efflux from dopaminergic neurons. 6th Int. Catecholamine Sym., June 1987.
104. Cubeddu, L.X., Talmaciu, R.K., Suarez-Roca, H. and Hoffmann, I.S.: Modulation of dopamine release from
striatal, limbic and cortical brain regions: dopamine-acetylcholine interactions. Int. Congress of Pharmacology, Aug.
1987.
105. Suarez-Roca, H. and Cubeddu, L.X.: Interactions between dopamine and acetylcholine in the olfactory tubercle
and nucleus caudate. Soc. for Neurosci., Nov. 1987.
106. Fuenmayor, N. and Cubeddu, L.X.: Niveles plasmaticos de verapamil en pacientes hipertensos que reciben
tratamiento con verapamil de liberacion inmediata y de liberacion prolongada. VII Congreso Latinoamericano de
Nefrologia, May 1988
107. Fuenmayor, N. and Cubeddu, L.X.: Efecto antihipertensivo sobre la conduccion auriculoventricular y efectos
secundarios del verapamil de liberacion inmediata (LI) y de liberacion prolongada (LP) en pacientes hipertensos. VII
Congreso Latinoamericano de Nefrologia, May 1988
108. Cubeddu, L.X., Buckley, J., Hedner T., Massotto, C. and Negro Vilar, A. Changes in atrial natriuretic peptides
(ANP), arginine vasopressin (AVP), renin activity (PRA), angiotensin II (A (() and aldosterone (ALD) induced by
calcium channel blockers and acute volume expansion. Am. Soc. Hypertension, July 1988.
109. Williams, D.M. and Cubeddu, L.X. Amlodipine pharmacokinetics in healthy volunteers. Am. Soc. Hypertension,
July 1988.
110. Lovenberg, T.W., Diliberto, P.A. and Cubeddu, L.X. Dopamine receptor control of 3H-dopamine and 14Cacetylcholine
release: effects of phorbol ester and forskolin. Society for Neuroscience, 14:1093, l988.
111. Talmaciu, R.K., Hoffmann, I.S., Calvo,R., Aquino, R. and Cubeddu, L.X. Prefrontal cortex (PFC) and striatum
(S) dopamine (DA) terminals: difer sensitivity to calcium depolarizing stimuli and K+ conductance inhibitors. III
Congress of Interamerican Pharmacology and Clinical Therapeutics, 1988.
112. Hoffmann, I.S., Talmaciu, R.K., Calvo, R., Aquino, R. and Cubeddu, L.X. Differential activation of protein
kinase C (PKC) by phorbol esters (Pu) in prefrontal cortex (PFC) and striatal (S) dopamine (DA) neurons. III Congress
of InterAmerican Pharmacology and Clinical Therapeutics, 1988.
113. Fuenmayor, N., Faggin, B.M. and Cubeddu, L.X. Pharmacokinetics of verapamil in essential hypertension:
effects of food intake. III Congress of Interamerican Pharmacology and Clinical Therapeutics, 1988.
25

LUIGI X. CUBEDDU
114. Cubeddu, L.X. Dopamine autoreceptors in prefrontal and limbic dopamine terminals. Meeting of The New York
Academy of Sciences "Presynaptic Receptors and the Question of Autoregulation of Neurotransmitter Release".
Philadelphia, December 4-5, 1989.
115. Hoffmann, I.S., Talmaciu, R.K., Aquino, R. and Cubeddu, L.X. Interaccion entre el forbol ester (PDBu) y los
receptores dopaminergicos D2 (Phorbol esters and D2 dopamine receptors). XL Anual Convention ASOVAC. Cumana
11/19/90. Acta Cientifica Venezol 41:p132, 1990.
116. Cubeddu L.X., Hoffmann I.S., Fuenmayor N.T. and Malave J. Eficacia del ondansetron (GR 38032F) en el control
de las nauseas y los vomitos inducidos por el cisplatino, papael de la serotonina (Efficacy of ondansetron and the role
of serotonin in cisplatinum-induced nausea and vomiting). XL Anual Convention ASOVAC. Cumana 11/19/90. Acta
Cientifica Venezol. 41:p138, 1990.
117. Alfieri A.B. and Cubeddu L.X. Efecto dela dieta baja en triptofano sobre la excrecion urinaria de 5hidroxiindolacetico
(5-HIAA) en voluntarios sanos (Effects of low tryptophane diet on urinary 5-HIAA in healthy
volunteers). XL Anual Convention ASOVAC. Cumana 11/19/90. Acta Cientifica Venezol. 41:p138, 1990
118. Gonzalez V., Andrade M., Fuenmayor N., Garcia I., Hoffmann I.S., Malave J. and Cubeddu L.X. Efecto
antiemetico de la dexametasona y la metoclopramida en pacientes con cancer que reciben quimioterapia con cisplatino
(Comparative antiemetic efficacy of dexamethasone and metoclopramide in cancer patients treated with cisplatin). XL
Anual Convention ASOVAC. Cumana 11/19/90. Acta Cientifica Venezol. 41:p235, 1990
119. Cubeddu L.X. Neuropharmacology of emesis in relation to clinical response: chemotherapy and radiotherapyinduced
emesis. Discussant. Emesis Round Table. Paris, Francia. 3-5 Feb. 1991.
120. Agneter E., Hoffmann I.S. and Cubeddu L.X. Autoinhibition of 3H-dopamine release from rabbit brain slices.
Marked differences in frequency dependence between prefrontal cortex and corpus striatum. 32nd Deutsche
Gesellschaft fur Pharmackologie und Toxicologie. Spring Meeting, March 12-15, Mainz. Naunyn Schmiedeberg's
Arch. Pharmacol. Suppl to Vol. 341: 1991; Abstract # 430.
121. Cubeddu L.X. Enlaces entre la Farmacología Cínica y la Basica. En Curso avanzado de farmacología clínica. II
Jornadas de la Sociedad Venezolana de Farmacologia y I Jornadas de la Sociedad Venezolana de Farmacología Clínica
y Terapéutica. Mayo 30 y 31 y Junio 1, 1991.
122. Cubeddu L.X., Fuenmayor N.T., Gonzalez V., Malavé J y Hoffmann I.S. Mecanismo de liberación de serotonina
por agentes antineoplásicos: efectos de la somatostatina. II Jornadas de la Sociedad Venezolana de Farmacologia y I
Jornadas de la Sociedad Venezol. de Farmacol. Clínica y Terapéutica. Caracas, Junio 1, 1991.
123. Cubeddu L.X., Hoffmann I.S. y Fuenmayor N.T. Liberación de serotonina por cisplatino: su relacion con las
nauseas y vomitos inducidos por agentes antineoplasicos. II Jornadas de la Sociedad Venezolana de Farmacologia y I
Jornadas de la Sociedad Venezol. de Farmacol. Clínica y Terapéutica. Caracas, Junio 1, 1991.
124. Cubeddu L.X., Garcia I., Malavé J y Hoffmann I.S. Efectos de la dacarbazina sobre el metabolismo de la
serotonina en pacientes con cancer: posible relación con las nauseas y los vómitos. II Jornadas de la Sociedad
Venezolana de Farmacologia y I Jornadas de la Sociedad Venezolana de Farmacología Clínica y Terapéutica. Caracas,
Junio 1, 1991.
125. Alfieri A y Cubeddu L.X. Efecto de la manipulación dietética y farmacológica sobre la excreción urinaria de acido
5-hidroxiindolacetico (5-HIAA) en voluntarios sanos. II Jornadas de la Sociedad Venezolana de Farmacologia y I
Jornadas de la Sociedad Venezol. de Farmacol. Clínica y Terapéutica. Caracas, Junio 1, 1991.
126. Hoffmann I.S., Talmaciu R.K. y Cubeddu L.X. Receptores presynapticos muscarínicos y liberación de dopamina:
interacción del carbacol y el forbolester. II Jornadas de la Sociedad Venezolana de Farmacologia y I Jornadas de la
Sociedad Venezolana de Farmacología Clínica y Terapéutica. Caracas, Mayo 31, 1991.
26

LUIGI X. CUBEDDU
127. Cubeddu, L.X. Conferencia Magistral: "La serotonina: el ansiógeno endógeno". VI Simposio latinoamericano de
psiquiatría biológica y I Jornadas venezolanas de psiquiatría biológica. Caracas 7 de Junio de 1991.
128. Cubeddu, L.X., Fuenmayor, N.T. and Ramirez Magbis.: Preliminary efficacy study of Benazepril/Amlodipine in
the treatment of patients with hypertension. Proc. of the XIV Interamerican Congress of Cardiology. May 23-27,
Orlando, Florida, 1992. Abstr # 063.
129. Ceglia A, Cedeño L, Guariguata J, Garcia I and Luigi X. Cubeddu. Infecciones respiratorias bajas adquiridas en la
comunidad. Proc. of the Internal Medicine Congress. Pto. La Cruz. May 1992; Abstr #.
130. Cubeddu LX. Mechanisms of the emetic response to chemotherapy and of the antiemetic action of 5-HT3 receptor
antagonists: clinical studies. 2nd International Symposium on Serotonin: from Cell Biology to Pharmacology and
Therapeutics. Sept 15-18, Houston, Texas, 1992. Abstr p 11.
131. Cubeddu L.X. Moderador-Organizador del Simposio-Mesa Redonda sobre: "Avances en la Farmacología de la
Serotonina". I Congreso IberoAmericano de Farmacología. España, Málaga. 21-24 de Septiembre de 1992.
132. Cubeddu L.X. Conferencia: Receptores serotonérgicos 5-HT3: papel en las náuseas y vómitos asociados a la
quimioterápia antineoplásica. I Congreso IberoAmericano de Farmacología. Málaga del 21-24 de Septiembre de 1992.
133. Cubeddu L.X. La Terapeutica de fin de siglo y del siglo XXI, en Forum: "La Facultad de Medicina en el Siglo
XXI": Jornadas ASOVAC. Auditorio Hospital Clinico Universitario. Nov 1992.
134. Cubeddu L.X., Lindley C and Hoffmann I.H. Serotonin (5-HT) release induced by chemotherapy (CT) in cancer
patrients. FASEB. 7: A690, 1993.
135. Cubeddu L.X. Invited Speaker and Lecturer: "Receptores Serotonergicos". II International Postgraduate Course on
"Pharmacological Receptors". March 15- April 2, 1993. Dpt. Pharmacology. School of Medicine. University of Chile.
136. Cubeddu L.X. Effects of antihypertensive drugs on adrenal steroids: its relationship with atherosclerosis. I
InterAmerican Symposium in Hypertension. Caracas, April 21-23, 1993.
137. Cubeddu L.X. Main lecturer: "Neuropharmacology". On International XXX Aniversary of AVEPANE. May 11-
14, 1993.
138. Alfieri A.B. and Cubeddu L.X. Inhibition of serotonin synthesis reduces chemotherapy-induced vomiting. Acta
Cient. Venezol. 44:1447, 1993. ASOVAC, Merida.
139. Cubeddu L.X. Invited Speaker. "Management and Mechanisms of Chemotherapy-Induced Nausea and Vomiting".
NOVA SouthEastern University; Miami ,Florida. March 18, 1994.
140. Castejon A.M., Aquino R, and Cubeddu L.X. Comparative effects of diazepam, chlordiazepoxide, buspirone and
ondansetron in punished and unpunished responding in pigeons. Proceed. XII Int Cong Pharmacol; Can J Physiol
Pharmacol. Vol 72, Suppl 1, 1994; Abstract #: P 13.7.20; p 363.
141. Cubeddu L.X., Garcia I., O'Connor D.T., and Parmer R.J. Effects of dacarbazine, nitrogen mustard and
cyclophosphamide on plasma chromogranin A and urinary levels of 5-hydroxyindoleacetic acid in cancer patients.
Proceed. XII Int Cong Pharmacol; Can J Physiol Pharmacol. Vol 72, Suppl 1, 1994; Abstract # P 13.24.38., p 457.
142. Cubeddu L.X., O'Connor D.T. and Parmer R.J. Cisplatin induces vomiting, increases plasma chromogranin A and
in serotonin metabolism. Proceed. XII Int Cong Pharmacol; Can J Physiol Pharmacol. Vol 72, Suppl 1, 1994; Abstract
# P13.24.14; p 453.
27

LUIGI X. CUBEDDU
143. Hoffmann I.S., Talmaciu R.K., Guevara B.H. and Cubeddu L.X. High potassium-induced facilitation of dopamine
release evoked by carabachol. Proceed. XII Int Cong Pharmacol; Can J Physiol Pharmacol. Vol 72, Suppl 1, 1994;
Abstract # P13.19.36; p 427.
144. Cubeddu L.X. Invited Speaker. Jornadas Iberoamericans conmemorativas del XXXI Aniversario de Avepane.
"Drugs, Neurotoxins and Brain Damage". Oct 5, 1994.
145. Cubeddu L.X. Invited Speaker. Title: Mechanisms of chemotherapy-induced emesis in cancer patients. In
"Mechanisms and Management of Nausea and Emesis Associated with Cancer Therapy. The Compleat Angler,
Marlow, Buckinghamshire, SL7 1RG, England. October 13 and 14, 1994.
146. Cubeddu L.X. Invited Speaker. Title: Receptores 5-HT3: aspectos clinicos y basicos. En el Simposio
"Farmacologia de los nuevos agonistas y antagonistas de los receptores serotonergicos centrales". XIV Latinamerican
Congress for Pharmacology. Nov 20-24, 1994; Santiago, Chile. Abstract # S12-4, p 75-76.
147. Faverola, G.F., Morales G.N. and Cubeddu LX. Role of Helicobacter Pylori in duodenal and gastric ulcer disease:
effects of treatment. XIV LatinAmerican Pharmacology Congress. Nov 20-24, 1994; Santiago, Chile. Abstract # CL6-
4, p 105.
148. Torrico F., Hoffmann I.S. and Cubeddu L.X. Effects of cisplatin on intestinal serotonin content. XIV
LatinAmerican Pharmacology Congress. Nov 20-24, 1994; Santiago, Chile. Abstract # P1-16, p 128.
149. DiBenedetto J, Cubeddu LX, Ryan T, Ksih J, Sciortino D and Beall C. Twice daily oral ondansetron effectively
prevents nausea and vomiting associated with cyclophosphamide-doxorubicin-based chemotheraypy. Proc. Am. Soc
Clin Oncol. 14: 538, 1995.
149. Cubeddu L.X. Invited Speaker. Serotonin Receptors: classification, effects and clinical applications. Panama
City. June 30, 1995.
150. Cubeddu, L.X. Invited Speaker. Role of serotonin in nausea and vomiting associated to cancer
chemotherapy,radiotherapy and postoperative procedures. Panama City. June 30, 1995.
151. Cubeddu, L.X. Invited Speaker. Pharmacology of antiemetic drugs. In advances in Pharmacotherapy. IX
Scientific meeting of the School of Pharmacy, and IV National Congress for Pharmaceutical Sciences. 10/31/1995.
152. Hoffmann IS, Talmaciu RK, Guevara BH, Aquino R and Cubeddu LX. Changes in resting membrane potential
facilitate carbachol-induced dopamine (DA) release from rabbit striatum. IX Scientific meeting of the School of
Pharmacy, and IV National Congress for Pharmaceutical Sciences. 10/30/ 1995
153. Faverola GF, Morales GN, Salomon MC, Bacalao RR, Lecuna V and Cubeddu L.X. Effects of bismuth salts
and ranitidine on Helicobacter Pylori and on healing and recurrence of duodenal and gastric ulcer disease. IX
Scientific meeting of the School of Pharmacy, and IV National Congress for Pharmaceutical Sciences. 10/30/ 1995.
154. Guevara BH, Hoffmann IS, Talmaciu RK, Aquino R and Cubeddu L.X. Effects of morphine on acetylcholine
release from rat striatum and olfactory tubercle. IX Scientific meeting of the School of Pharmacy, and IV National
Congress for Pharmaceutical Sciences. 10/30/ 1995.
155. Cubeddu L.X. and Hoffmann IS. Characteristics of vomiting associated with treatment with cisplatin. IX
Scientific meeting of the School of Pharmacy, and IV National Congress for Pharmaceutical Sciences. 10/30/ 1995.
156. Talmaciu RK, Hoffmann IS, Aquino R and Cubeddu L.X. Reciprocal antagonism between phorboldibutyrate
and muscarinic agonists on dopamine release from rabbit striatum and prefrontal cortex. . IX Scientific meeting of
the School of Pharmacy, and IV National Congress for Pharmaceutical Sciences. 10/31/1995.
28

LUIGI X. CUBEDDU
157. Castejon AM, Cubeddu L.X. and Aquino R. Evaluation of ansiolytic activity of ondansetron under operant
behavior in pigeons. IX Scientific meeting of the School of Pharmacy, and IV National Congress for
Pharmaceutical Sciences. 10/31/1995.
158. Torrico F, Hoffmann IS and Cubeddu L.X. Effects of cisplatin on gut serotonin content. IX Scientific meeting
of the School of Pharmacy, and IV National Congress for Pharmaceutical Sciences. 10/31/1995.
159. Tawid TB, Faverola GF, Morales GN, Salomon MC, Tombazzi CM, Landaeta T, Lecuna V and Cuebddu L.X.
Helicobacter pylori in upper gastrointestinal pathologies. IX Scientific meeting of the School of Pharmacy, and IV
National Congress for Pharmaceutical Sciences. 10/31/1995.
160.Guevara BH, Hoffmann IS, Talmaciu RK, Aquino R and Cubeddu L.X. Changes in acetylcholine release from
rat striatum and olfactory tubercle induced by kainic acid. IX Scientific meeting of the School of Pharmacy, and IV
National Congress for Pharmaceutical Sciences. 10/31/1995.
161. Guevara BH, Hoffmann IH and Cubeddu L.X. Differential effect of kainic on choline acetyltransferase activity
in striatum and olfactory tubercle. IX Scientific meeting of the School of Pharmacy, and IV National Congress for
Pharmaceutical Sciences. 11/01/1995.
162. Cubeddu L.X. Differences in the mechanisms by which antineoplastic drugs induce emesis in cancer patients.
IX Scientific meeting of the School of Pharmacy, and IV National Congress for Pharmaceutical Sciences.
11/01/1995.
163. Roa CM, Hoffmann IS and Cubeddu L.X. Screening of catecholamine producing tumors. IX Scientific
meeting of the School of Pharmacy, and IV National Congress for Pharmaceutical Sciences. 11/01/1995.
164. Castejon AM, Ayala C and Cubeddu L.X. Effects of ondansetron on morphine-induced dopaminergic
hyperactivity in nucleus accumbens and corpus striatum of the rat. IX Scientific meeting of the School of
Pharmacy, and IV National Congress for Pharmaceutical Sciences. 11/01/1995.
165. Torrico F, Hoffmann IS and Cubeddu L.X. Effects of cisplatin on intestinal serotonin content. XLV Annual
Meeting of the Venezuelan Society for the Development of Science. 19-24 Nov, 1995. Acta Cient Venezol. 46:
supp 1, p79, 1995.
166. Cubeddu L.X. and Hoffmann IS. Emesis associated to treatment with cisplatin: markers of serotonin
release.XLV Annual Meeting of the Venezuelan Society for the Development of Science. 19-24 Nov, 1995. Acta
Cient Venezol. 46: supp 1, p79, 1995.
167. Cubeddu L.X. Differences in the mechanisms by which anticancer drugs induce emesis in cancer patients.
XLV Annual Meeting of the Venezuelan Society for the Development of Science. 19-24 Nov, 1995. Acta Cient
Venezol. 46: supp 1, p79, 1995.
168. Faverola GF, Tawid TB, Morales GN, Salomon MC, Tomazzi CM, Landaeta T, Lecuna V and Cubeddu L.X.
Association between Helicobacter Pylori and upper gastrointestinal pathologies. XLV Annual Meeting of the
Venezuelan Society for the Development of Science. 19-24 Nov, 1995. Acta Cient Venezol. 46: supp 1, p79, 1995.
169. Morales GN, Faverola GF, , Salomon MC, Bacalao R Lecuna V and Cubeddu L.X Helicobacter Pylori in
duodenal and gastric ulcer disease. XLV Annual Meeting of the Venezuelan Society for the Development of
Science. 19-24 Nov, 1995. Acta Cient Venezol. 46: supp 1, p79, 1995.
170. Roa CM, Hoffmann IS and Cubeddu L.X. Screening of catecholamine-producing endocrine tumors:
pheochromocytomas and neuroblastomas. XLV Annual Meeting of the Venezuelan Society for the Development of
Science. 19-24 Nov, 1995. Acta Cient Venezol. 46: supp 1, p86, 1995.
29

LUIGI X. CUBEDDU
171.Guevara BH, Hoffmann IS, Talmaciu RK, Aquino R and Cubeddu L.X. Effects of kainic acid on acetylcholine
release from caudate nucleus and olfactory tubercle. XLV Annual Meeting of the Venezuelan Society for the
Development of Science. 19-24 Nov, 1995. Acta Cient Venezol. 46: supp 1, p86, 1995.
172. Guevara BH, Hoffmann IS and Cubeddu L.X. Effects of kainic acid on striatal and limbic cholinergic neurons.
XLV Annual Meeting of the Venezuelan Society for the Development of Science. 19-24 Nov, 1995. Acta Cient
Venezol. 46: supp 1, p86, 1995.
173. Guevara BH, Hoffmann IS, Talmaciu RK, Aquino R and Cubeddu L.X. Modulation of acetylcholine (AC)
release from striatal and limbic cholinergic neurons by dopaminergic and opioidergic receptors. XLV Annual
Meeting of the Venezuelan Society for the Development of Science. 19-24 Nov, 1995. Acta Cient Venezol. 46:
supp 1, p86, 1995.
174. Hoffmann IS, Talmaciu RK, Guevara BH, Aquino R and Cubeddu L.X. High potassium-induced facilitation of
dopamine release induced by carbachol.. XLV Annual Meeting of the Venezuelan Society for the Development of
Science. 19-24 Nov, 1995. Acta Cient Venezol. 46: supp 1, p87, 1995.
175. Talmaciu RK, Hoffmann IS, Aquino R and Cubeddu L.X. Interactions between cholinergic muscarinic
receptors and phorbol dibutyrate on dopamine release from rabbit straitum and prefrontal cortex. XLV Annual
Meeting of the Venezuelan Society for the Development of Science. 19-24 Nov, 1995. Acta Cient Venezol. 46:
supp 1, p87, 1995.
176. Castejon AM, Aquino R and Cubeddu L.X. Comparative effects of diazepam, chlordiazepoxide, buspirone
and ondansetron on punished and unpunished responding in pigeons. XLV Annual Meeting of the Venezuelan
Society for the Development of Science. 19-24 Nov, 1995. Acta Cient Venezol. 46: supp 1, p87, 1995.
177. Cubeddu L.X. Invited Speaker. Main Lecture. “New drugs for Old Diseases”. XXIII CentroAmerican
Congress for Pharmaceutical Sciences. Panama City. Nov 1996.
178. Cubeddu L.X. Invited Speaker. Psychopharmacology Session. “Pathophysiology and Treatment of
Depression”. XXIII CentroAmerican Congress for Pharmaceutical Sciences. Panama City. Nov 1996.
179. Cubeddu L.X. Invited Speaker. Conference entitled Öndansetron: anxyolitic, antidopaminergic and antiemetic
actions. 16/07/97. At Institute of Pharmacology and Toxicology, School of Medicine, University of Bonn,
Germany. July, 1997.
180. Cubeddu LX, Guevara BH and Hoffmann IS. Changes in dopamine and serotonin metabolism induced by
kainic acid injections in ventral and dorsal striatal regions of the rat brain. J Neurochem 69: S67 B, 1997. 16th
ISN/28th ASN Meeting, Boston, Massachusetts, USA. July 1997.
181. Guevara BH, Hoffmann IS and Cubeddu LX. Differential effects of Kainic acid on choline acetyltransferase
activity (CAT) of dorsal and ventral regions of the rat brain. J Neurochem 69: S72D, 1997. 16th ISN/28th ASN
Meeting, Boston, Massachusetts, USA. July 1997.
182. Cubeddu LX. Invited Speaker. Mechanisms of insulin resistance and salt sensitivy in hypertensive patients.
XV LatinAmerican Congress for Pharmacology. Cartagena de Indias, Colombia, August 27-31, 1997.
183. Cubeddu LX. Invited Speaker. Sigma receptors and modulation of 5-HT3 and NMDA channels: effects of
neurosteroids. XV LatinAmerican Congress for Pharmacology. Cartagena de Indias, Colombia, August 27-31, 1997.
184. Cubeddu LX. Simposion Chairman and Coordinator: Basic Neuropharmacology. XV LatinAmerican Congress
for Pharmacology. Cartagena de Indias, Colombia, August 27-31, 1997.
185. Cubeddu LX. Chairman and coordinator of “Psychopharmacology: models for studies in Neuropharmacology
I”. XV LatinAmerican Congress for Pharmacology. Cartagena de Indias, Colombia, August 27-31, 1997.
30

LUIGI X. CUBEDDU
186. Castejon AM, Paez X, Hernandez L and Cubeddu LX. The use of intravenous microdialysis for studying the
metabolism of serotonin in cancer patients treated with cisplatin. XV LatinAmerican Congress for Pharmacology.
Cartagena de Indias, Colombia, August 27-31, 1997.
187. Alfieri AB and Cubeddu LX. Nitric oxide release induced by cyclophosphamide in the rat bladder can be
prevented by a NK1-receptor antagonist. XV LatinAmerican Congress for Pharmacology. Cartagena de Indias,
Colombia, August 27-31, 1997.
188. Torrico F, Zarpa N, Martinez C, Bermudez H, Noya O and Cubeddu LX. Development of a method to study
circulating chromogranin A (CgA) employing synthetic peptides. XV LatinAmerican Congress for Pharmacology.
Cartagena de Indias, Colombia, August 27-31, 1997.
189. Castejon AM, Aquino R and Cubeddu LX. Effects of low and high punishment-induced behavioral suppression
on the anxiolytic action of benzodiazepines, buspirone and ondansetron. XV LatinAmerican Congress for
Pharmacology. Cartagena de Indias, Colombia, August 27-31, 1997.
190. Talmaciu RK, Guevara BH, Aquino R, Hoffmann IS and Cubeddu LX. Effects of potassium channel blockers
on carbachol-induced dopamine release. XV LatinAmerican Congress for Pharmacology. Cartagena de Indias,
Colombia, August 27-31, 1997.
191. Hoffmann IS, Talmaciu RK, Guevara BH, Aquino R and Cubeddu LX. Differential effects of the protein
kinase C activator, phorbol 12, 13, dibutirate, on carbachol-induced facilitation of dopamine release from the rabbit
corpus striatum. XV LatinAmerican Congress for Pharmacology. Cartagena de Indias, Colombia, August 27-31,
1997.
192. Guevara BH, Cubeddu RJ, Perez M, Hoffmann IS and Cubeddu LX. Kainic acidic neurotoxicity on the
cholinergic neurons of the dorsal and ventral regions of the corpus striatum of the rat. XV LatinAmerican Congress
for Pharmacology. Cartagena de Indias, Colombia, August 27-31, 1997.
193. Guevara BH, Torrico F, Cubeddu RJ, Perez M, Hoffmann IS and Cubeddu LX. Differential effects of kainic
acid on dopamine and serotonin turnover of the dorsal and ventral striatal regions of the rat. XV LatinAmerican
Congress for Pharmacology. Cartagena de Indias, Colombia, August 27-31, 1997.
194. Cubeddu LX, Fuenmayor NT and Moreira E. Abnormal insulin-mediated glucose disposal in salt sensitive
hypertensives: salt sensitivity an independent cardiovascular risk factor. XV LatinAmerican Congress for
Pharmacology. Cartagena de Indias, Colombia, August 27-31, 1997.
195. Cubeddu LX, Fuenmayor NT and Moreira E.Hyperinsulinemia in obese hypertensives: incidence, effects of
antihypertensive drugs and its relation with dihydroepiandrosterone. XV LatinAmerican Congress for
Pharmacology. Cartagena de Indias, Colombia, August 27-31, 1997.
196. Cubeddu LX. Invited Speaker. Regulation and functional role of 5-HT3 receptors. XIX LatinAmericn
Congress for Physiological Sciences. Caracas, Venezuela Sept 5th, 1997.
197. Castejon AM, Ayala C and Cubeddu LX. Antidopaminergic effect of the 5-HT3 antagonists, ondansetron, on
the limbic system and striatum of the rat. XIX LatinAmerican Congress for Physiological Sciences. Caracas,
Venezuela Sept 5th, 1997.
198. Alfieri AB, Rodriguez-Plaza LG and Cubeddu LX. Effects of a cardiac rehabilitation program on basal and
exercise-induced production of NO in patients with coronary artery disease. XIX LatinAmericn Congress for
Physiological Sciences. Caracas, Venezuela Sept 5th, 1997.
199. Cubeddu LX. Invited Speaker. Salt sensitivity and Insulin resistance in essential hypertension. Dept of
Pharmacology. School of Pharmacy. Central University of Venezuela. October 22, 1997.
31

LUIGI X. CUBEDDU
200. Miller KJ, Gonzalez HA and Cubeddu LX. Metformin may allosterically modulate 5-HT3 receptor binding.
Soc. Neurosci. Abst. 1997, 23, 975.
201. Cubeddu LX. Invited Speaker. Investigator View Point. Simposium on " Clinical Trials in Latin America: new
perspectives". Fisrt Venezuelan Congress for Pharmacology. May 6-9, 1998.
202. Cubeddu LX. Invited Speaker.Salt sensitivity: a cardiovascular risk factor. Simposium on Advances in
Cardiovascular Diseases. Fisrt Venezuelan Congress for Pharmacology. May 6-9, 1998.
203. Cubeddu L.X. Invited Speaker. Pharmacy and Health in the 21 st Century. Main Lecture of the Annual School
of Pharmacy Meeting at the Central University of Venezuela. May 13, 1998.
204. Cubeddu LX, Faverola G, Molderings GJ, Bonisch Hand Gothert M. Mechanisms by which Substance P
enhances 5-HT effects mediated by 5-HT3 receptors in N1E-115 neuroblastoma cells. XIIth International Congress
of Pharmacology. Naunyn-Schmiedeberg´s Archives of Pharmacology 358:S1, P8..34; R111, 1998.
205. Guevara BH, Ayala C, Hoffmann IS and Cubeddu LX. Changes in aminoacid levels induced by stereotaxic
injection of kainic acid (KA) into caudate putamen and olfactory tubercle of the rat. XIIth International Congress of
Pharmacology. Naunyn-Schmiedeberg´s Archives of Pharmacology 358:S1, P35.107; R54, 1998.
206. Torrico FM, Noda A, Matinez C, Bermudez HM, Noya O and Cubeddu LX. Immunogenecity of syntghetic
peptides derived from human chromogranin A (CGA). XIIth International Congress of Pharmacology. Naunyn-
Schmiedeberg´s Archives of Pharmacology 358:S2, P48.2; R467, 1998.
207. Cubeddu LX, Alfieri AB and Rodriguez-Plaza LG. Urinary cGMP excretion, exercise training and cardiac
rehabilitation. XIIth International Congress of Pharmacology. Naunyn-Schmiedeberg´s Archives of Pharmacology
358:S2, P22.5; R660, 1998.
208. Alfieri AB and Cubeddu LX. GR205171, a NK1 receptor antagonist reduces cisplatin induced nephrotoxicity
in the rat. . XIIth International Congress of Pharmacology. Naunyn-Schmiedeberg´s Archives of Pharmacology
358:S2, P42.2; R741, 1998.
209. Cubeddu L.X. Invited Speaker: Latin American COX-2 Science Summit. COX-2 vs. COX-1: gastrointestinal
side-effect profiles. Miami, Florida. March 11-13, 1999.
210. Cubeddu L.X. Invited Speaker.First Venezuelan Congress for Hypertension.Title: Insulin and Hypertension.
Caracas, Venezuela. June 6-10, 1999.
211. Cubeddu LX. Invited Speaker. XXXII Venezuelan Congress of Cardiology. Salt sensitivity: a cardiovascular
risk factor. July 28-31, 1999.
212. Guevara BH, Hoffmann IS and Cubeddu LX. Dorsal striatum modulates neurotransmitter activities in the
ipsilateral ventral striatum.. Joint Meeting of the Eur Soc Neurochem and Internat Soc Neurochem. Aug 8-14, 1999,
Berlin, Germany. J Neurochem 73:Abstr # 843, suppl 1999.
213. Cubeddu L.X. Invited Speaker.”Multiple Risk Factors associated with Salt Sensitivity”. First Meeting on
Research and Teaching. Graduate Program in Pharmacology. School of Pharmacy. Central University of Venezuela.
October 4-8, 1999.
214. Cubeddu L.X. Symposium Coordinator and Speaker. “COX-2 inhibitors”. First Meeting on Research and
Teaching. Graduate Program in Pharmacology. School of Pharmacy. Central University of Venezuela. October 4-8,
1999.
32

LUIGI X. CUBEDDU
215. Cubeddu L.X, Hoffmann IS, Jimenez E, Roa CM, Baldonedo R, Palermo C and Cubeddu RJ. Multiple
Cardiovascular Risk factors Associated with Salt sensitivity. 5 th International Symposium on Multiple Risk Factors
in Cardiovascular Disease: Global Assessment and Intervention. Venice, Italy, October 28-31,1999 (p31 abstract
book).
216. Cubeddu L.X, Alfieri AB and Rodriguez-Plaza L.G. Nitric oxide excretion: a possible marker of physical
fitness and endothelial heath. 5 th International Symposium on Multiple Risk Factors in Cardiovascular Disease:
Global Assessment and Intervention. Venice, Italy, October 28-31,1999 (page 41 abstract book).
217. Cubeddu L.X. Invited Speaker. Pharmacy and health on the 21 st Century. VII Nacional Congress of
Pharmaceutical Sciences. Merida, Venezuela. April 03, 2000.
218. Cubeddu L.X. Invited Speaker. “Salt Sensitivity: a Cardiovascular Risk Factors”. March 22, 2000.
Department of Veterans Affairs, Medical Center, West Palm Beach, Florida, USA.
219. Cubeddu L.X. and Hoffmann I.S. Microalbuminuria and systolic blood pressure in obesity.In Proceedings of
the XV Scientific Meeting of the American Society for Hypertension. N. York. Am J Hypertens. 113:#4, part2,
p96A, 2000. Abstract # E045.
220. Castejon A.M., Hoffmann I.S., Cubeddu R.J. , Silveira H and Cubeddu L.X. Insulinotropic effect of l-arginine
and glucose in control subjects and in hypertensive,obese, hyperinsulinemic patients. Proceedings of the XV
Scientific Meeting of the American Society for Hypertension, N York. Am J Hypertens. 113:#4, part2, p96A, 2000.
Abstract # E046.
221. Alfieri A.B., Hoffmann I.S. and Cubeddu L.X. Reduced nitric oxide (NO) excretion during high salt intake in
salt sensitive individuals. Proceedings of the XV Scientific Meeting of the American Society for Hypertension, N
York. Am J Hypertens. 113:#4, part2, p96A, 2000. Abstract # E045.
222. Cubeddu L.X. Invited Speaker: “Nitric Oxide and salt sensitivity in normotensive and hypertensive
individuals” XIX SouthAmerican Congress of Cardiology and XXXIII Venezuelan Congress of Cardiology.
Caracas, Venezuela June 6-10, 2000.
223. Cubeddu L.X. Invited Speaker “Insulin resistance in Arterial Hypertension”. Symposium on “New aspects in
the therapy of hypertension”. XVI Latinamerican Congress of Pharmacology, II Iberoamerican Congress of
Pharmacology; Aguas de Lindoia, Sao Paulo, Brazil, 13-17 September 2000.
224. Cubeddu L.X. Main Conference. Invited Speaker. “Arterial Hypertension, Insulin and Glucose: who is the
villain?” XVI Latinamerican Congress of Pharmacology, II Iberoamerican Congress of Pharmacology; Aguas de
Lindoia, Sao Paulo, Brazil, 13-17 September 2000.
225. Guevara BH, Cespedes G, Rodriguez A, Campos M, Albarran B, Rodriguez H y Cubeddu L.X. Behavioral and
neuropathological effects of the central injection of crotalus vegrandis venom. XVI Latinamerican Congress of
Pharmacology, II Iberoamerican Congress of Pharmacology; Aguas de Lindoia, Sao Paulo, Brazil, 13-17 September
2000. Poster 01.152. p109.
226. Torrico F, Noda A, Bermudez H, Noya O and Cubeddu L.X. Identification of chromogranin (CGA)-derived
peptides by western blot, in cancer patients receiving treatment with cisplatin. XVI Latinamerican Congress of
Pharmacology, II Iberoamerican Congress of Pharmacology; Aguas de Lindoia, Sao Paulo, Brazil, 13-17 September
2000.Poster 22.011, p396.
227. Hoffmann IS, Leandro G, Roa C and Cubeddu LX. Salt sensitivity: its relationship with hyperinsulinemia and
hyperglycemia. L Annual Meeting Nov 19-24, 2000, Caracas, Venezuela. Acta Cientifica Venezolana Vol 51:
Suplemento 2: pp 92.
33

LUIGI X. CUBEDDU
228. Hoffmann IS, Roa C, Leandro G, and Cubeddu LX. Dysmetabolic syndrome and microalbuminuria. L Annual
Meeting Nov 19-24, 2000, Caracas, Venezuela. Acta Cientifica Venezolana Vol 51: Suplemento 2: pp 92.
229. Hoffmann, IS, Roa, CM, Alfieri, AB, Baldonedo, RM and Cubeddu LX. Glucose, insulin and nitric oxide in
salt sensitivity human subjects. III Latin-American Congress of Hypertension. Nov 1-4, 2000, Caracas, Venezuela.
230. Castejon, A, IS Hoffmann, R. Cubeddu, H. Silveira and Cubeddu LX. Comparative effects of l-arginine
infusion and oral glucose load in plasma insulin levels. L Annual Meeting Nov 19-24, 2000, Caracas, Venezuela.
Acta Cientifica Venezolana Vol 51: Suplemento 2: pp 92
231. Guevara BH, Campos, M., Céspedes, G and Cubeddu, LX: Melatonin prevention of cholinergic damage
depends on kainic-acid induced neuronal degeneration. L Annual Meeting Nov. 19-24, 2000, Caracas, Venezuela.
232. Hoffmann, IS, Roa, CM, Alfieri, AB, Baldonedo, RM and Cubeddu LX. Glucose, insulin and nitric oxide in
salt sensitivity human subjects. III Latin-American Congress of Hypertension. Nov 1-4, 2000, Caracas, Venezuela.
233. Castejon, AM, Hoffmann, IS, Baldonedo, RM and Cubeddu LX. Effects of l-arginine on blood pressure and on
insulin release. III Latin-American Congress of Hypertension. Nov 1-4, 2000, Caracas, Venezuela
234. Fuenmayor, N, Moreira, E and Cubeddu LX Salt sensitivity and insulin resistance in essential hypertension. III
Latin-American Congress of Hypertension. Nov 1-4, 2000, Caracas, Venezuela.
235. Malave A, Cubeddu LX and Xu X. Cyclophosphamide-induced iNOS expression and NO production in
primary cultures of rat bladder cells. Soc Neuroscience. 26:538.11 (2000). Annual Meeting in New Orleans.
236. Alfieri AB, and Cubeddu LX. Role of NK1 tachykinin receptors and nitric oxide in cyclophosphamide-induced
cystitis in rats. Pharmaceutical Congress of the Americas March 27-28,2001, Orlando, Florida. USA. Abstr 2028,
page 101.
237. Cubeddu L.X., Invited Speaker. QT prolongation and fatal arrhythmia: clinical implications and effects of
drugs. Internal Medicine and Cardiology fellows. Mt Sinai Medical Center, Miami, FL, USA, June 12, 2001.
238. Guevara, B., Campos, M., Cespedes, G and Cubeddu, L. X.: Efecto de la melatonina sobre la
neurodegeneracion colinergica inducida por acido kainico en el estriado. VI Neurosciences School. Montevideo,
Uruguay, April 2001
239. Guevara, B., Campos, M., Cespedes, G and Cubeddu, L.X.: Neuroprotective effects of melatonin and
methylisothiourea on cholinergic damage induced by kainic acid in the rat striatum. J. Neurochemistry. XVI
International Congress of Neurochemistry. Buenos Aires, Argentina. August 2001
240. Torrico, FM, Noda, JR., Bermudez, H., Rizo, L., Noya, O. and Cubeddu, LX: Immunogenecity of diferent
regions on Chromogranin A. LI Annual meeting of the Venezuelan Association for the Development of Science.
ASOVAC. San Cristóbal, 18-23 November, 2001
241. Torrico, FM, Roa, CM, Hoffmann, IS, Jiménez, E., Baldonedo, RM, Palermo, C., Aponte, L. and Cubeddu,
LX: Role of 5HT3 receptors on the gastrointestinal side effects associated with metformin treatement. LI Annual
meeting of the Venezuelan Association for the Development of Science. ASOVAC. San Cristóbal, 18-23 November,
2001.
242. Alfieri, AB and Cubeddu LX: Cyclophosphamide-induced induction of nitric oxide syntahse: role of substance
P. LI Annual meeting of the Venezuelan Association for the Development of Science. ASOVAC. San Cristóbal, 18-
23 November, 2001
34

LUIGI X. CUBEDDU
243. Guevara, BH, Campos, M., Cespedes G, Rodriguez, A and Cubeddu, LX: Behavioral and histological changes
induced by icv administration of crotalus vegrandis venom in rats. Presented at: VII Congress of the South-
American Pharmaceutical Federation. Caracas, November 2001. Honorific Mention!
244. Guevara, B., Campos, M., Cespedes, G and Cubeddu, L.X.: Distant histological changes induced by direct
intrastriatal injection of kainic acid in rats: effects of neuroprotective agents. Presented at: VII Congress of the
South-American Pharmaceutical Federation. Caracas, November 2001.
245. Alfieri, AB and Cubeddu, LX: Nitric Oxide Synthase: role of inducible but not neuronal NOS in the
pathogenesis of cyclophosphamide-induced neurogenic cystitis. Presented at: VII Congress of the South-American
Pharmaceutical Federation. Caracas, November 2001.
246. Torrico, FM, Noda, A., Bermudez, H., Noya, O. and Cubeddu, LX: Identification of chromogranin A (CGA) by
western-blot, in cancer patients receiving cisplatin chemotherapy. . Presented at: VII Congress of the South-
American Pharmaceutical Federation. Caracas, November 2001.
247. Roa, CM., Torrico, FB., Hoffmann, IS and Cubeddu, LX: Metformin-induced gastrointestinal side effects: role
of 5-HT3 receptors. . Presented at: VII Congress of the South-American Pharmaceutical Federation. Caracas,
November 2001.
248. Roa., CM., Hoffmann, IS and Cubeddu, LX: SERDEF: service for the detction of Pheochromocytomas.
Presented at: VII Congress of the South-American Pharmaceutical Federation. Caracas, November 2001.
249. Hoffmann, IS., Roa., CM., Aponte, L., Franco, Y., Nuñez, R. and Cubeddu, LX: Prevalence of “syndrome X”
in a healthy adult population . Presented at: VII Congress of the South-American Pharmaceutical Federation.
Caracas, November 2001. Prize to the best scientific paper!
250. Castejon, AM., Hoffmann, IS, Roa, CM y Cubeddu, LX: Hemodynamic effects of glucose and l-arginina in
obese hypertensives. Presented at: VII Congress of the South-American Pharmaceutical Federation. Caracas,
November 2001.
251. Mora, IS., Blanco, SF., Alfieri, AB, Hoffmann, IS., Roa, CM and Cubeddu, LX: Salt sensitivity: its relationship
with insulin, glucose and nitric oxide levels. Presented at: VII Congress of the South-American Pharmaceutical
Federation. Caracas, November 2001.
252. Guevara, BH, Campos, M., Cespedes G, Rodriguez, A and Cubeddu, LX: Neurotoxicity of kainic acid and
crotalus vegrandis venom in striatum of the rat. Presented at: XI Annual Scientific Congress. Pharmacy School.
Central University of Venezuela. Caracas, March 2002. Poster # 24, p 13.
253. Campos, M., Guevara, BH, Campos, M., Cespedes G, Rodriguez, A and Cubeddu, LX: Neuroprotection of
histological effects induced by intrastriatal kainic acid. Presented at: XI Annual Scientific Congress. Pharmacy
School. Central University of Venezuela. Caracas, March 2002. Poster # 25, p 13.
254. Castejon Am, Hoffmann, IS and Cubeddu LX. Comparative effects of L-arginine infusion in obese
hypertensives and lean normotensives: blood pressure, heart rate and insulinlevels. P454. XVII Annual Scientific
Meeting and Exposition of the American Society of Hypertension. NY, May 14-18, 2002.
255.Cubeddu LX and Hoffmann IS. Silent cardiovascular risk factors associated with salt sensitivity in healthy
subjects. P520. XVII Annual Scientific Meeting and Exposition of the American Society of Hypertension. NY, May
14-18, 2002.
256. Linares BE., Cubeddu L.X. and Alfieri AB. Role of nitric oxide synthase and cyclooxygenase on
cyclophosphamide-induced cystitis in rats. The Pharmacologist. 44:#2, Supp 1, page A226, Abstract # 133.12.
XIVth World Congress of Pharmacology. July 7-12,2002. Moscone Convention Center, San Francisco, CA.
35

LUIGI X. CUBEDDU
257. Cubeddu L.X. and Suarez-Roca H. Inhibition of 5HT uptake induces the storage of 5HT in catecholaminergic
terminals. The Pharmacologist. 44:#2, Supp 1, page A245, Abstract # 138.9. XIVth World Congress of
Pharmacology. July 7-12,2002. Moscone Convention Center, San Francisco, CA.
258. Cubeddu LX., Alfieri AB., Castejon AM, Rathinavelu A and Hoffmann IS. Salt intake, urinary nitric oxide
metabolite excretion and Gly460Trp alpha-adducin polymorphism. Amer Soc Hypertens 18 th Annual Scientific
Meeting, May 2003. Abstract # P-112.
259. Castejon AM, Hoffmann IS, Rathinavelu A and Cubeddu LX., . Cardiovascular risk factors, salt sensitivity and
alpha-adducin polymorphism in Venezuelan Subjects. Amer Soc Hypertens 18 th Annual Scientific Meeting, May
2003. Abstract # P-110.
260. Jaime R. Bracero, Ana M Castejon, Irene Hoffmann and Luigi X. Cubeddu C242T Polymorphism of NADPH
Oxidase p22 Phox Gene, Salt Sensitivity and Cardiovascular Risk Factors. 25 th Annual Pharmacy Student Research
Conference-Eastern States.
261. Rachel Tavares de Melo, Ana M Castejon, Irene Hoffmann and Luigi X. Cubeddu. G298A and 4a/b
Endothelial Nitric Oxide Synthase Gene Polymorphisms, Salt Sensitivity and Cardiovascular Risk Factors. 25 th
Annual Pharmacy Student Research Conference-Eastern States.
262. Alfieri, A.B., Hoffmann, IS, Nuñez-B, R, Roa, CM, García, RS, Castejon,AM y Cubeddu, LX: Association of
alpha-adducin polymorphism with salt sensitivity , LDL-Cholesterol, post-load glucose and nitric oxide in healthy
individuals. IX Venezuelan Congress of Endocrinology and Metabolism, Caracas, May, 11-15, 2004.
263. Hoffmann, IS, Roa, CM, Garcia, RS, Nuñez-B, R, Suarez, Y, Rivas, CE,Alfieri, AB and Cubeddu, LX:
Prevalence of cardiovascular and metabolic risk factors in an apparently healthy Venezuelan adults. IX Venezuelan
Congress of Endocrinology and Metabolism, Caracas, May, 11-15, 2004.
264. Nuñez-B, Hoffmann, IS, Roa, CM, Garcia, RS, Aponte, LA, Medina-S, H.,Alfieri, AB and Cubeddu, LX:
Upper levels of microalbuminuria and cardiovascular and metabolic risk in asymptomatic, apparently healthy,
Venezuelans. IX Venezuelan Congress of Endocrinology and Metabolism, Caracas, May, 11-15,2004.
265. Alfieri, AB, Hoffmann, IS, Nuñez-B, R, Roa, CM, Garcia, RS, Castejon, AM and Cubeddu, LX. From
epidemiology to genes: incidence of high blood pressure, salt sensitivity and alpha adducin polymorphysm in a
population of apparently healthy adults. XXI Congresso Nazionale Della Societa Italiana Dell ìpertesione arteriosa,
Florence, Italy, October, 5-8, 2004.
266. Hoffmann, IS, Roa, CM, García, RS, Alfieri, AB, Nuñez-B, R, Suarez, Y, Rivas, CE, and Cubeddu, LX.
Dysmetabolic cardiovascular syndrome in an apparently healthy Venezuelans. IV Latin American Congress on
Hypertension, Caracas, Venezuela, 26 to 29 October, 2004.
267. Cubeddu LX. Inhibition of endothelial cholesterol synthesis by statins: impact on nitric oxide formation and
vascular function. IV Latin American Congress on Hypertension. Caracas, Venezuela, 26 to 29 October, 2004.
268. Luigi X. Cubeddu, Rachel Tavares-Mordwinkin, Ana Castejon, Anna Alfieri, and Irene Hoffmann. Role of
genetic factors in salt sensitivity. IV Latin American Congress on Hypertension. Caracas, Venezuela, 26 to 29
October, 2004.
269. Torres-Ruiz, AC Córdova-Valero, MD Martínez-Zamora, MA Osorio-Lopez, GA Jiménez-Valerio, MI
Escobar-Guillen, JA Sánchez-Ferrer, L Marcano-Figueroa, CG Romero-Alfonzo, KE Gomes-Martinez, JV Gómez-
Barrios, RS García-Cubas , CM Roa-Ramos, L Cubeddu-Ximenez, IR Hoffmann-Sanchez. Prevalence of the
metabolic síndrome and risk factors in a sample of the city of Caracas. VII Jornadas Cientificas Estudiantiles,
Universidad Central de Venezuela, 21 al 26 de Noviembre de 2005. Prize best poster in the area of Clinical
Pharmacology.
36

LUIGI X. CUBEDDU
270. Jiménez-Valerio, MI Escobar-Guillen, MA Osorio-Lopez, MD Martínez-Zamora, CL Torres-Ruiz, AC
Córdova-Valero, L Marcano-Figueroa, CG Romero-Alfonzo, JA Sánchez-Ferrer, KE Gomes-Martinez, JV Gómez-
Barrios, RS García-Cubas, CM Roa-Ramos, L Cubeddu-Ximenez, IR Hoffmann Sánchez. Cardiovascular and
metabolic risk factors associated with obesity. VII Jornadas Cientificas Estudiantiles, Universidad Central de
Venezuela, 21 al 26 de Noviembre de 2005.
271. KE Gomes-Martinez, JA Sánchez-Ferrer, AC Córdova-Valero, GA Jiménez-Valerio, MI Escobar-Guillen, L
Marcano-Figueroa, MA Osorio-Lopez, CG Romero-Alfonzo, MD Martínez-Zamora, CL Torres-Ruiz, JV Gómez-
Barrios, RS García-Cubas, CM Roa-Ramos, L Cubeddu-Ximenez, IR Hoffmann-Sanchez. Comparison of glucose,
colesterol and triglycerides by capillary and venous sampling methods. VII Jornadas Cientificas Estudiantiles,
Universidad Central de Venezuela, 21 al 26 de Noviembre de 2005.
272. L Marcano-Figueroa, CG Romero-Alfonzo, JA Sánchez-Ferrer, CL Torres-Ruiz, AC Córdova-Valero, MA
Osório-Lopez, MD Martínez-Zamora, MI Escobar-Guillen, GA Jiménez-Valerio, KE Gomes-Martinez, JV Gómez-
Barrios, J Hernández, RS García-Cubas, CM Roa-Ramos, L Cubeddu-Ximenez, IR Hoffmann-Sanchez.
Dislipidemia: relationship with other cardiovascular and metabolic risk factors. VII Jornadas Cientificas
Estudiantiles, Universidad Central de Venezuela, 21 al 26 de Noviembre de 2005.
273. MD Martínez-Zamora, MA Osorio-Lopez, GA Jiménez-Valerio, MI Escobar-Guillen, L Marcano-Figueroa,
CG Romero-Alfonzo, JA Sánchez-Ferrer, CL Torres-Ruiz, AC Córdova-Valero. KE Gomes-Martinez, JV Gómez-
Barrios, RS García-Cubas, CM Roa-Ramos, L Cubeddu-Ximenez, IR Hoffmann-Sanchez. Role of age and gender in
determining prevalence of cardiovascular and metabolic risk factors. II Jornadas de Extensión Universitaria 29-30
de Noviembre, 1-2 de Diciembre, 2005 UCV
274. Guevara, B.H., Céspedes, G., y Cubeddu, LX. Neuroprotective effects of melatonin on kainic acid-induced
neurotoxicity in striatum. I International Congress of Therapeutics. October 29th 2005. Carcas, Venezuela.
275. Guevara, B.H., Céspedes, G., Alfieri, A.B and Cubeddu, LX. Role of nitric oxide synthase isoforms on kainic
acid-induced cholinergic damage and NO levels in rat striatum. International Meeting of Neurochemistry. Berlin,
Germany. August, 2005
276. Tristano AG, Castejon AM, Castro A and Cubeddu LX. Statins Withdrawal Increases Angiotensin II-mediated
Phosphorylation of p-38 MAK and ERK1/2 in cultured Vascular Smooth Muscle Cells. Abst # 157. Ist International
Congress of Therapeutics. Oct 27-29. Caracas, Venezuela.
277. Hoffmann S, Irene, Roa C, Magaly, Garcia S, Robert, Nuñez-Bogesits Rosaura, Cubeddu X, Luigi. Role of
Hyperinsulinemia in Salt Sensitivity. Abst # 148. Ist International Congress of Therapeutics. Oct 27-29. Caracas,
Venezuela.
278. Hoffmann S, Irene, Nuñez-Bogesits, Rosaura, Roa C, Magaly, Garcia S, Robert, Cubeddu X, Luigi. Metabolic
Syndrome of Cardiovascular Risk Factors. Abst # 147. Ist International Congress of Therapeutics. Oct 27-29.
Caracas, Venezuela.
279. Hoffmann S, Irene, Alfieri B, Anna, Nuñez-Bogesits Rosaura, Roa C, Magaly, Garcia S, Robert, Cubeddu X,
Luigi. Effects of Life-Style changes and metformin in glucose-tolerant hypernsulinemic patients. Abstr #146.
280. Guevara, B.H., Céspedes, G., Alfieri, A.B y Cubeddu, LX. Role of nitric oxide synthase isoforms on kainic acidinduced
cholinergic damage and NO levels in rat striatum. International Meeting of Neurochemistry. August, 2005
281. Luigi X. Cubeddu and Irene S. Hoffmann. Salt Sensitivity and the Metabolic Syndrome. ISHIB 2006 Annual
Scientific Meeting. Atlanta Georgia, June 24-26 th , 2006.
282. Cubeddu LX, Alfieri AB, Hoffmann IS. Threshold for microalbuminuria must be lowered: effects of a lifestylemetformin
intervention in overweight-obese normoalbuminuric subjects. J Hypertens, 25: S344, Abstract # P37.185.
European Meeting on Hypertension. June 15-19, 2007. Milan, Italy.
37

LUIGI X. CUBEDDU
283. Cubeddu LX, Alfieri AB, Hoffmann IS. Effects of a lifestyle changes and metformin on salt sensitivity and
nitric oxide metabolism in obese salt sensitive obese subjects. J Hypertens, 25: S344, Abstract # P37.186. European
Meeting on Hypertension. June 15-19, 2007. Milan, Italy.
284. Cubeddu L.X. Invited Speaker. “The Renin Angiotensin Aldosterone System: An Update”. VIII Congress of
the Venezuelan Society for Hypertension. Caracas, Venezuela. September 23-25, 2009.
285. Cubeddu LX. Invited Speaker. “Prediabetes: mechanisms, prevalence, diagnostic criteria and treatment”. Ist
Inter-American Congress on Diabetes. July 15 th -17 th , Maracaibo, Venezuela. September 23-25, 2009.
38

LUIGI X. CUBEDDU
BOOK CHAPTERS
1. Goldstein, D.J., Finklelman, S., Cubeddu, L.X., Talmaciu, R. and Nahmod, V.E. Angiotensin and DBH in the
cerebrospinal fluid of normotensive and essential hypertensive patients. In: "The central action of angiotensin and
related hormones." (Ed. Buckley & Ferrario) 563, P. Press, 1977.
2. Cubeddu, L.X. Plasma and cerebrospinal fluid dopamine-beta-hydroxylase activity, in animal stress and human
hypertension. In "Catecholamines: basic and clinical frontiers". Vol. 2, p. 1509-1511, 1979.
3. Trifaro, J.M. and Cubeddu, L.X. Exocytosis as the mechanism of noradrenergic transmitter release. In: "Trends in
Autonomic Pharmacology". Vol. l, p. 195-250, Ed. S. Kalsner, Urban & Schwarzenberg, 1979.
4. Cubeddu, L.X. Release of dopamine-beta-hydroxylase from noradrenergic nerve terminals and adrenal medulla:
discrepancy with in vivo plasma measurements. Proc. Third Congress of Hungarian Pharmacol. Soc. 137-138, 1979.
5. Cubeddu, L.X., Hoffmann, I.S. and Paris, V. Effects of phosphodiesterase inhibitors and cyclic AMP on
norepinephrine and dopamine release. In: "Presynaptic Receptors". Ed. Langer et. al. Pergamon Press, Oxford and
New York, p. 311-315, 1980.
6. Cubeddu, L.X. and Goldstein, D.J. Reduced dopamine-beta-hydroxylase activity in the cerebrospinal fluid of
essential hypertensive patients. Perspectives in Cardiovascular Research, Vol. 6, Series Editor A.M. Katz. In:
"Central Nervous System Mechanisms in Hypertension." Ed. J.P. Buckley and C.M. Ferrario. Raven Press, New
York, p. 153-159, 1981.
7. Viveros, O.H., Wilson, S.P., Cubeddu, L.X. and Kirshner, N. Opioid peptides in human adrenal medulla and
pheochromocytoma. In: "Degradation of Endogenous Opioids: Its Relevance in Human Pathology and Therapy." Ed.
S. Ehrenpreis and F. Sicuteri. Raven Press, New York, pp. 11-24, 1983.
8. Cubeddu, L.X. Calcium channel blockers as monotherapy in hypertension. In: "Current Status of Calcium Channel
Blockers in Hypertension". Ed. S.E. Epstein. Biomedical Information Corporation, pp. 65-83, 1986.
9. Cubeddu, L.X. Comparative effects of verapamil and propranolol in hypertension. In: "Hypertension - The Next
Decade". Ed. A. Fleckenstein and J.H. Laragh. Churchill Livingstone, pp. 101-105, 1987.
10. Cubeddu, L.X. Rate and duration of stimulation: As a determinant of drug action on the CNS. In Recent Advances
in Pharmacology and Therapeutics. Excerpta Medica., International Congress Series 839. Eds. M. Velasco, A. Israel,
E. Romero and H. Silva. Elsevier, Amsterdam, pp 307-313, 1989.
11. Cubeddu, L.X. and Kessler, J.M. Special Clinical Situations: Cardiovascular Therapy in Patients with Organ
Failure. Section III. In "Cardiovascular Drug Therapy". Ed. F.H.Messerli. Philadelphia, W.B.Saunders, 1990.
12. Cubeddu, L.X. Modulation of dopamine release from corpus striatum, limbic regions and prefrontal cortex by
presynaptic receptors. In "Presynaptic Regulation of Neurotransmitter Release; a Handbook". Ed. JJ Feigenbaum and
M Hannani, Freund Publishing House Ltd., London, England. In Press, 1990 (33 typed pages)
13. Cubeddu L.X., Hoffmann I.S. and Talmaciu R.K. Is the release of dopamine from medial prefrontal cortex
modulated by presynaptic receptors ? Comparison with nigrostriatal and mesolimbic terminals. In Presynaptic receptors
and the question of autoregulation of neurotransmitter release. Eds. Stanley Kalsner and Thomas Westfall. The New
York Academy of Sciences. vol 604; p 452-461, 1990.
14. Bonnet, J-J, Benmansour, S., Chab, N., Costentin, J., Parker, E.M. and Cubeddu, L.X. Ionic and temperature
dependence of the 3H-dopamine specific uptake and 3H-GBR 12783 or 3H-mazindol specific binding on the dopamine
neuronal carrier. Advances in the Biosciences. Presynaptic Receptors and Neuronal Transporters. Eds. Langer SZ.,
Galzin AM, and Costentin J. Pergamon Press, 1991; 189-192.
39

LUIGI X. CUBEDDU
15. Cubeddu L.X., Hoffmann I.S., Fuenmayor N.T. and Finn A. In cyclophosphamide-containing regimens:
antagonism of serotonin S3 receptors with ondansetron prevents nausea and emesis. In "Quality of Life in Oncology
Practice and Research". Eds. N.S. Tchekmedyian and D.F.Cella. Dominus Publishing Co.,Inc. New York. 1991; p 113-
118.
16. Cubeddu L.X. The role of serotonin in chemotherapy-induced Emesis in Cancer Patients. In "Antiemetic Therapy:
Current Status and Future Prospects". Eds. E. Diaz Rubio and M. Martin-Jimenez. Creaciones Elba SA., Madrid, Spain.
1992; p 40-55.
17. Cubeddu LX and Hoffmann IS. Mechanisms of the emetic response to chemotherapy and of the antiemetic action
of 5-HT3-receptor antagonists: clinical studies. In Serotonin: from cell biology to pharmacology and therapeutics. Eds.
PM Vanhoutte, PR Saxena, R Paoletti, N Brunello and AS Jackson. Kluwer Academic Publishers., London. 1994; p
171-178.
18. Cubeddu, L.X., Alfieri, A.B. and Hoffmann, I.S. Clinical evidence for the role of serotonin in acute emesis induced
by cytotoxics. In: Serotonin and Emesis: a decade of progress. Eds. Davies, Andrews and Reynolds. Oxforf Clin.
Communications. 1995;pp142-149.
19. Cubeddu L.X. and Fuenmayor N.T. Interaction between salt intake and glucose metabolism in salt sensitive
hypertensives. In: New Advances in Cardiovascular Physiology and Pharmacology. Eds. M. Velasco and
R.Hernandez. Elsevier Science B.V. 1998; pp 105-111.
20. Cubeddu L.X. and Fuenmayor N.T. Euglycemic hyperinsulinemia in obese hypertensives: effects of
antihypertensives. In: New Advances in Cardiovascular Physiology and Pharmacology. Eds. M. Velasco and
R.Hernandez. Elsevier Science B.V. 1998; pp 223-227.
21. Fuenmayor N, Moreira E and Cubeddu LX. Salt Sensitivity is associated with insulin resistance in essential
hypertension. In: Year Book of Cardiology. Eds RS Schlant, JJ Collins, BJ Gersh, TP Graham, NM Kaplan and AL
Waldo. Mosby, St Louis, MO 1999; pp 40-42.
22. Alfieri AB, Castejon AM, Hoffmann IS, Garcia R, Nunez B, Roa CM and Cubeddu LX. Nitric oxide in
hypertension: role of the Gly-460 alpha-adducin polymorphism. In: Current Advances of Hypertension. Eds. Rafael
Hernandez-Hernandez and Maria J. Armas-Hernandez. Medimond Int Proc 2005; pp:33-38.
23. Alfieri AB, Castejon AM, Hoffmann IS, Garcia R, Nunez B, Roa CM and Cubeddu LX. Effects of age on the
prevalence of the cardiovascular dysmetabolic syndrome. In: Current Advances of Hypertension. Eds. Rafael
Hernandez-Hernandez and Maria J. Armas-Hernandez. Medimond Int Proc 2005; pp:75-80.
24. Lippincott’s Illustrated Reviews: Pharmacology, 3 rd Edition, Editors: Richard A Harvey and Pamela C.
Champ. Reviewed and rewrote Chapters 3 through 7, 2006
25. Lippincott’s Illustrated Reviews: Pharmacology, 4 th Edition, Editor: Richard A Harvey. Collaborating Editors:
Richard Finkel, Luigi Cubeddu and Michelle A. Clark.
UNIT 4: Drugs Affecting Cardiovascular System.
Chapters: 16: Heart Failure
Chapter 17: Antiarrhytmics
Chapter 18: Antianginal drugs
Chapter 19: Antihypertensives
Chapter 22: Diuretics.
26. Lippincott’s Illustrated Reviews: Pharmacology, 5 th Edition, Editor: Richard A Harvey. Collaborating Editors:
Michelle A. Clark, Richard Finkel and Jose Rey. 2011.
40